В статьях на сайте использованы следующие сокращения:

• °F — температура по Фаренгейту
• °C — температура по Цельсию
• 5-НТ — 5-гидроксииндолуксусная кислота мочи
• АБ — антибиотик(и)
• АБЛА — аллергический бронхолегочный аспергиллез
• АБТ — антибактериальная терапия
• АВ — атриовентрикулярный
• АГ — артериальная гипертензия
• АГн — антиген
• АД — артериальное давление
• АДГ — антидиуретический гормон
• АДС — анатоксин дифтерийно-столбнячный
• АДС-М — анатоксин дифтерийно-столбнячный (малые дозы)
• АДФ — аденозиндифосфорная кислота, аденозиндифосфат
• АКДС — анатоксин коклюшно-дифтерийно-столбнячный
• АКТГ — адренокортикотропный гормон
• АКШ — аортокоронарное шунтирование
• АЛТ — аланинаминотрансфераза
• амер. — американский
• АМК — азот мочевины крови
• АМФ — аденозинмонофосфорная кислота, аденозинмонофосфат
• АНА — антинуклеарные антитела
• анат. — анатомический
• англ. — английский
• АНЦА — антинейтрофильные цитоплазматические антитела
• АПФ — ангиотензин-превращающий фермент
• АРВТ — антиретровирусная терапия
• АРП — активность ренина в плазме крови
• АСК — аминосалициловая кислота
• ACT — аспартатаминотрансфераза
• АТл — антитело
• АТФ — аденозинтрифосфорная кислота, аденозинтрифосфат
• АуД — аутосомно-доминантный
• АуР — аутосомно-рецессивный
• АФП — α-фетопротеин
• АФС — антифосфолипидный синдром
• АХЭ — ацетилхолинэстераза
• АЦХ — ацетилхолин
• АЧТВ — активированное частичное тромбопластиновое время
• БА — бронхиальная астма
• БАД — биологически активная добавка
• БАЛ — бронхоальвеолярный лаваж
• БАР — биполярное аффективное расстройство (I или II типа)
• БКК — большой круг кровообращения
• БЛНПГ — блокада левой ножки пучка Гиса
• БМСЭ — бюро медико-социальной экспертизы
• БП — брюшная полость
• БПНПГ — блокада правой ножки пучка Гиса
• БРА — блокатор рецепторов ангиотензина
• БРМ — базовые реанимационные мероприятия
• БРНС — быстро разрешившееся необъяснимое событие
• БЦЖ — бацилла Кальметта-Герена
• в т.ч. — в том числе
• в. — век
• в/ — внутри... в сложносоставных словах (напр.
• в/сосудистый, в/черепной и т.п.)
• в/а — внутриартериально
• в/в — внутривенно
• в/к — внутрикожно
• в/м — внутримышечно
• вв. — века
• в-во — вещество
• ВВЭ — военно-врачебная экспертиза
• ВГД — внутриглазное давление
• ВГЧ — вирус герпеса человека
• ВДП — верхние дыхательные пути
• ВЖК — внутрижелудочковое кровоизлияние
• ВЗК — воспалительные заболевания кишечника
• ВЗОМТ — воспалительные заболевания органов малого таза
• ВИП — вазоактивный интестинальный пептид
• ВИЧ — вирус иммунодефицита человека
• ВМП — высокотехнологичная медицинская помощь
• ВМС — внутриматочное средство (спираль)
• ВН — вирусная нагрузка
• ВНС — вегетативная нервная система
• ВОВ — Великая Отечественная война
• ВОГМ — высокогорный отек головного мозга
• ВОЗ — Всемирная организация здравоохранения
• ВОЛ — высокогорный отек легких
• ВОМК — врач, осуществляющий медицинский контроль
• ВОП — врач общей практики
• ВПВ — верхняя полая вена
• ВПГ — вирус простого герпеса
• ВПР — врожденные пороки развития
• ВПС — врожденный порок сердца
• ВПЧ — вирус папилломы человека
• ВРТ — вспомогательные репродуктивные технологии
• ВСО — водно-солевой обмен
• ВЧД — внутричерепное давление
• ВЧИВЛ — высокочастотная искусственная вентиляция легких (HFV)
• ВЭБ — вирус Эпштейна-Барр
• г — грамм
• г. — год
• Г-6-ФД — глюкозо-6-фосфатдегидрогеназа
• ГАМК — гамма-аминомасляная кислота
• ГБ — гипертоническая болезнь
• ГБН — гемолитическая болезнь новорожденного
• ГБО — гипербарическая оксигенация
• ГГПТ — γ-глутамилтранспептидаза
• ГЗТ — гиперчувствительность замедленного типа
• гист. — гистологический
• ГК — грудная клетка
• ГКМП — гипертрофическая кардиомиопатия
• ГКС — глюкокортикостероид(ы)
• ГЛГ — гемофагоцитарный лимфогистиоцитоз
• ГЛПС — геморрагическая лихорадка с почечным синдромом
• ГМ — головной мозг
• ГМ-КСФ — гранулоцитарно-макрофагальный колониестимулирующий фактор
• ГМФ — гуанозинмонофосфат
• ГнРГ — гонадотропин-рилизинг-гормон
• ГНТ — гиперчувствительность немедленного типа
• ГПОД — грыжа пищеводного отверстия диафрагмы
• ГРДС — гипоксическая реакция дыхательной системы
• греч. — греческий
• ГТФ — гуанозинтрифосфат
• ГУС — гемолитико-уремический синдром
• Гц — герц
• ГЭБ — гематоэнцефалический барьер
• ГЭР — гастроэзофагеальный рефлюкс
• ГЭРБ — гастроэзофагеальная рефлюксная болезнь
• дБ — децибел
• ДВС — диссеминированное внутрисосудистое свертывание
• ДГПЖ — доброкачественная гиперплазия предстательной железы
• ДГТ — дигидротестостерон
• ДД — дифференциальная диагностика, дифференциально-диагностический
• ДДБА — длительно действующие β₂-агонисты
• ДДК — дифференциально-диагностический критерий (критерии)
• ДИ — доверительный интервал
• ДК — диагностический критерий
• ДКА — диабетический кетоацидоз
• ДКМП — дилатационная кардиомиопатия
• ДМЖП — дефект межжелудочковой перегородки
• ДМПП — дефект межпредсердной перегородки
• ДМС — добровольное медицинское страхование
• ДН — дыхательная недостаточность
• ДНК — дезоксирибонуклеиновая кислота
• ДНТ — дефекты нервной трубки
• ДОФА — дигидроксифенилаланин
• ДП — дыхательные пути
• ДПК — двенадцатиперстная кишка
• ДПМ — дата последней менструации
• ДПП — давление в правом предсердии
• др. — другие
• ДТП — дорожно-транспортное происшествие
• ДЦП — детский церебральный паралич
• ЕД — единица действия
• ЖВП — желчевыводящие пути
• ЖДА — железодефицитная анемия
• ЖЕЛ — жизненная емкость легких
• ЖКБ — желчекаменная болезнь
• ЖКК — желудочно-кишечное кровотечение
• ЖКТ — желудочно-кишечный тракт
• ЖНВЛП — жизненно необходимые и важные лекарственные препараты (список, перечень)
• ЖТ — желудочковая тахикардия
• ЗВУР — задержка внутриутробного развития
• ЗЛ — здоровые люди (лица)
• ЗНО — злокачественное новообразование
• ЗО — здравоохранение
• ЗОЖ — здоровый образ жизни
• ЗСН — застойная сердечная недостаточность
• иАПФ — ингибиторы ангиотензин-превращающего фермента
• ИБС — ишемическая болезнь сердца
• ИВЛ — искусственная вентиляция легких
• ИГКС — ингаляционные глюкокортикостероиды
• ИЗЛ — интерстициальные заболевания легких
• ИКД — имплантируемый кардиовертер-дефибриллятор
• ИКП — иммунокомпрометированные пациенты
• ИЛ — интерлейкин
• ИЛДБ — интегрированное лечение детских болезней
• ИМ — инфаркт миокарда
• ИМАО — ингибитор(ы) моноаминоксидазы
• ИМбпБТ — инфаркт миокарда без подъема сегмента ST
• ИМП — инфекция мочевых (мочевыводящих) путей
• ИМпST — инфаркт миокарда с подъемом сегмента ST
• ИМТ — индекс массы тела
• ИОЛ — интраокулярная линза
• ИПП — ингибиторы протонной помпы (протонного насоса)
• ИППП — инфекции, передаваемые половым путем
• ИСС — индивидуальные спасательные средства
• истор. — историческое
• итал. — итальянский
• ИТП — идиопатическая тромбоцитопеническая пурпура
• ИТШ — инфекционно-токсический шок
• ИФА — иммуноферментный анализ
• КА — коронарная(ые) артерия(и)
• КАГ — коронарография
• КБМП - качество и безопасность медицинской помощи
• кВ — киловольт
• кг — килограмм
• КДБА — короткодействующие β2-агонисты
• КДД — конечно-диастолическое давление
• КДО — конечно-диастолический объем
• КДР — конечно-диастолический размер
• кит. — китайский
• ккал — килокалория
• кл. — клетки, клеток
• КМП — качество медицинской помощи
• КоА — коэнзим А, кофермент А
• КОЕ — колониеобразующая единица
• КОК — комбинированные оральные контрацептивы
• КПТ — когнитивно-поведенческая терапия
• КР — клинические рекомендации
• КСД — конечно-систолическое давление
• КСО — конечно-систолический объем
• КСР — конечно-систолический размер
• КТ — компьютерная томография
• КТВР — компьютерная томография высокого разрешения
• КТГ — кардиотокография
• КФК — креатинфосфокиназа
• КЩС — кислотно-щелочное состояние
• л — литр
• л/о — ложноотрицательный
• л/п — ложноположительный
• ЛА — легочная артерия
• ЛАГ — легочная артериальная гипертензия лат. — латинский
• ЛГ — лютеинизирующий гормон
• ЛДГ — лактатдегидрогеназа
• ЛЖ — левый желудочек
• ЛОР — имеющий отношение к оториноларингологии (ЛОР-врач, ЛОР-органы)
• ЛП — лекарственный препарат
• ЛПВП — липопротеины высокой плотности
• ЛПНП — липопротеины низкой плотности
• ЛПОНП — липопротеины очень низкой плотности
• ЛПУ — лечебно-профилактическое учреждение ЛС — лекарственное средство
• ЛУ — лимфатический(ие) узел(лы)
• ЛФК — лечебная физкультура
• м.б. — может (мог, могут, могли) быть
• М/Ж — соотношение мужчин и женщин
• максД — максимальная доза
• максНД — максимальная начальная доза
• максРД — максимальная разовая доза
• максСД — максимальная суточная доза
• МАНК — метод амплификации нуклеиновых кислот
• МАО — моноаминоксидаза
• МВП — мочевыводящие пути
• мг — миллиграмм
• МДБ — мышечная дистрофия Беккера
• МДД — мышечная дистрофия Дюшенна
• МДМА — метилендиоксиметамфетамин
• ME — международная единица
• мед. — медицинский
• мес — месяц
• МЖ — молочная железа
• МЖП — межжелудочковая перегородка
• М3 — министерство здравоохранения
• мин — минут(а)
• минД — минимальная доза
• минСД — минимальная суточная доза
• МКБ — мочекаменная болезнь
• МКБ-10 — Международная классификация болезней 10-го пересмотра
• МКБ-11 —Международная классификация болезней 11-го пересмотра
• мкВ — микровольт
• мкг — микрограмм
• МКК — малый круг кровообращения
• мкл — микролитр
• мл — миллилитр
• млн — миллион
• млрд — миллиард
• мм — миллиметр
• мм рт.ст. — миллиметр ртутного столба
• ммоль — миллимоль
• МНН — международное непатентованное наименование
• МНО — международное нормализованное отношение
• МО — медицинская организация
• МП — медицинская помощь
• МПС — мочеполовая система
• МР — магнитно-резонансный
• МР-венография — МРТ вен и синусов головного мозга мРНК — матричная РНК
• МРТ — магнитно-резонансная томография
• МРХПГ — магнитно-резонансная холангиопанкреатография
• мс — миллисекунда
• МСКТ — мультиспиральная компьютерная томогра-
• фия
• МСЭ — медико-социальная экспертиза
• МТ — масса тела
• мтДНК — митохондриальная дезоксирибонуклеиновая кислота
• МТР — масса тела при рождении
• н.э. — нашей эры
• НА — нервная анорексия
• НАД — никотинамидадениндинуклеотид
• НАДН — никотинамидадениндинуклеотид (восстановленный)
• НАДФ — никотинамидадениндинуклеотидфосфат
• НАЖБП — неалкогольная жировая болезнь печени напр. — например
• НАСГ — неалкогольный стеатогепатит
• НБ — нервная булимия
• НДО — негативный детский опыт
• нед — недели
• нем. — немецкий
• НИВЛ — неинвазивная вентиляция легких
• НЛР — нежелательная лекарственная реакция
• нм — нанометр
• НМГ — низкомолекулярный гепарин
• НМИЦ — национальный медицинский исследовательский центр
• НМП — неотложная медицинская помощь
• НМТ — низкая масса тела
• НПА — нормативно-правовой акт
• НПВ — нижняя полая вена
• НПВС — нестероидные противовоспалительные средства
• НС — нервная система
• НСГ — нейросонография
• НЭК — некротический энтероколит
• НЯК — неспецифический язвенный колит
• ОАК — общий анализ крови
• ОАМ — общий анализ мочи
• ОАП — открытый артериальный проток
• ОБП — органы брюшной полости
• ОГБ — острая горная болезнь
• ОГМ — отек головного мозга
• ОДН — острая дыхательная недостаточность
• ОЖСС — общая железосвязывающая способность сыворотки
• ОЗ — организация здравоохранения
• ок. — около
• ОКР — обсессивно-компульсивное расстройство
• ОКС — острый коронарный синдром
• ОЛЛ — острый лимфобластный лейкоз
• ОМП - оказание медицинской помощи
• ОМС — обязательное медицинское страхование
• ОМТ — органы малого таза
• ОНМК — острое нарушение мозгового кровообращения
• ОНМП — отделение неотложной (медицинской) помощи
• ОНМТ — очень низкая масса тела
• ООЗ — органы (организации/управления) здравоохранения
• ООЛ — остаточный объем легких
• ООН — Организация Объединенных Наций
• ОПЖ — ожидаемая продолжительность жизни
• ОПН — острая почечная недостаточность
• ОПП — острое повреждение почек
• ОПСС — общее периферическое сосудистое сопротивление
• ОРВИ — острая респираторная вирусная инфекция
• ОРДС — острый респираторный дистресс-синдром
• ОРЗ — острое респираторное заболевание
• ОРИТ — отделение реанимации и интенсивной терапии (ICU)
• ОСВО — общее содержание воды в организме
• ОФВ — объем форсированного выдоха
• ОФВ₁ — объем форсированного выдоха за 1-ю секунду
• ОЦК — объем циркулирующей крови
• п.з. — поле зрения (микроскопа)
• п/к — подкожно
• ПАВ — психоактивные вещества
• ПВ — протромбиновое время
• ПВК — периферический венозный катетер
• ПВЛ — перивентрикулярная лейкомаляция
• Пг — простагландин
• ПГГ — программа государственных гарантий оказания гражданам РФ бесплатной медицинской помощи
• ПДКВ — положительное давление конца выдоха (PEEP)
• ПЖ — правый желудочек
• ПЖЖ — поджелудочная железа
• ПЖК — подкожная жировая клетчатка (гиподерма)
• ПКА — почечный канальцевый ацидоз
• ПКМД — поясно-конечностная мышечная дистрофия
• ПЛСГ — пятнистая лихорадка Скалистых гор
• ПМДР — предменструальное дисфорическое расстройство
• ПМК — пролапс митрального клапана
• ПМС — предменструальный синдром
• ПМСП — первичная медико-санитарная помощь
• ПНА — передняя нисходящая артерия
• ПНЖК — полиненасыщенные жирные кислоты
• ПОРИТ — педиатрическое отделение реанимации и интенсивной терапии
• ПОТ — постуральная ортостатическая тахикардия
• ППВ — пневмококковая полисахаридная вакцина
• ППОАК — прямые пероральные антикоагулянты ППТ — площадь поверхности тела
• ПСА — простатоспецифический антиген
• ПСВ — пиковая скорость выдоха
• ПСВХ — прогрессирующий семейный внутрипеченочный холестаз
• ПТ — психотерапия
• ПТВ — протромбиновое время
• ПТГ — паратиреоидный гормон
• ПТИ — протромбиновый индекс
• ПТСР — посттравматическое стрессовое расстройство
• ПФЭ — пищевой фолатный эквивалент
• ПЦР — полимеразная цепная реакция
• ПШГ — пурпура Шенлейна-Геноха
• ПЩЖ — паращитовидные железы
• ПЭТ — позитронно-эмиссионная томография р/ —раз в ... (с, мин, ч, сут и т.п.)
• РА — ревматоидный артрит
• РААС — ренин-ангиотензин-альдостероновая система
• разг. — разговорный
• разл. — различный
• РАС — расстройство аутистического спектра
• РДС — респираторный дистресс-синдром
• рим. — римский
• РИФ — реакция иммунофлюоресценции
• РКИ — рандомизированные клинические исследования
• РКМП — рестриктивная кардиомиопатия
• РИГА — реакция непрямой гемагглютинации
• РНК — рибонуклеиновая кислота
• РОГК — рентгенография (рентгенограмма) органов грудной клетки
• РОЛСНС — рекомендации по оценке и лечению при сортировке в неотложных ситуациях
• РИГА — реакция прямой гемагглютинации
• р-р — раствор
• р-ритель — растворитель
• РРК — рецепторы ретиноевой кислоты
• РРМ — расширенные реанимационные мероприятия
• РСВ — респираторно-синцитиальный вирус
• РСД — расстройство стереотипных движений
• РСК — реакция связывания комплемента
• РТГА — реакция торможения гемагглютинации
• РТНГА — реакция торможения непрямой гемагглютинации
• РФ — Российская Федерация
• РХР — ретиноевые Х-рецепторы
• РЧА — радиочастотная абляция
• РЭС — ретикулоэндотелиальная система
• с — секунда
• св-во — свойство
• СВДС — синдром внезапной детской смерти
• СГЯ — синдром гиперстимуляции яичников
• СД — сахарный диабет
• СД-1 — сахарный диабет 1 -го типа
• СД-2 — сахарный диабет 2-го типа
• СДВГ — синдром дефицита внимания и гиперактивности
• СЕ — субъединица
• СЖК — свободные жирные кислоты
• СЗСТ — системное(ые) заболевание(я) соединительной ткани
• СИЗ — средства индивидуальной защиты
• СИОЗС — селективный ингибитор обратного захвата серотонина
• СИОЗСН — селективные ингибиторы обратного захвата серотонина и норэпинефрина
• СКА — серповидно-клеточная анемия
• СКВ — серповидно-клеточная болезнь
• СКВ — системная красная волчанка
• СКФ — скорость клубочковой фильтрации
• СЛР — сердечно-легочная реанимация
• см — сантиметр
• см вод.ст. — сантиметр водяного столба
• СМЖ — спинномозговая жидкость
• СМИ — средства массовой информации
• СМО — страховая медицинская организация
• СМП — скорая медицинская помощь
• СМЭ — судебно-медицинская экспертиза
• СН — сердечная недостаточность
• СНСАДГ — синдром неадекватной секреции АДГ
• СОАС — синдром обструктивного апноэ сна (во сне)
• совр. — современный
• СОЭ — скорость оседания эритроцитов
• СПИД — синдром приобретенного иммунодефицита
• СПКЯ — синдром поликистозных яичников
• СПОН — синдром полиорганной недостаточности
• СРБ — С-реактивный белок
• СРК — синдром раздраженного кишечника
• СрСД — средняя суточная доза
• ССВ — синдром Стерджа-Вебера
• ССВР — синдром системной воспалительной реакции
• ССЗ — сердечно-сосудистые заболевания
• ССС — сердечно-сосудистая система
• СССУ — синдром слабости синусового узла
• СТ — Синдром Туретта
• СТГ — соматотропный гормон
• СТР — стойкое (хроническое) моторное или вокальное тикозное расстройство
• сут — сутки
• СХУ — синдром хронической усталости
• т.д. — так далее
• т.е. — то есть
• т.к. — так как
• т.о. — таким образом
• т.п. — тому подобное
• Т3 — трийодтиронин
• Т4 — тироксин
• ТАНК — тест амплификации нуклеиновых кислот
• ТБС — тазобедренный сустав
• ТГВ — тромбоз глубоких вен
• ТГСК — трансплантация гемопоэтических стволовых клеток
• ТИА — транзиторная ишемическая атака
• ТИАБ — тонкоигольная аспирационная биопсия
• ТМО — твердая мозговая оболочка
• TH — торговое наименование лекарственных средств
• ТПГГ — территориальная программа государственных гарантий оказания гражданам РФ бесплатной медицинской помощи
• ТПМ — травматическое повреждение мозга
• ТТ — температура тела
• ТТГ — тиреотропный гормон
• ТФР — трансформирующий фактор роста
• ТЦА — трициклические антидепрессанты
• тыс. — тысяча
• ТЭД —транзиторная эритробластопения детского возраста
• ТЭЛА — тромбоэмболия легочной артерии
• ТЭО — тромбоэмболические осложнения
• УЗДС — ультразвуковое дуплексное сканирование
• УЗИ — ультразвуковое исследование
• устар. — устаревший
• УФ — ультрафиолетовый
• УФО — ультрафиолетовое облучение
• ФАП — фельдшерско-акушерский пункт
• ФВ — фракция выброса
• ФВД — функции внешнего дыхания
• ФЖ — фибрилляция желудочков
• ФЖЕЛ — форсированная жизненная емкость легких
• ФЗ — Федеральный закон
• физиол. — физиологический
• ФК — функциональный класс
• ФКС — фиброколоноскопия
• ФКУ — фенилкетонурия
• ФН — физическая нагрузка
• ФНО — фактор некроза опухоли
• ФОМС — федеральный фонд обязательного медицинского страхования
• ФОС — фосфорорганические соединения
• ФП — фибрилляция предсердий
• фр. — французский
• ФСГ — фолликулостимулирующий гормон
• ФСГС — фокально-сегментарный гломерулосклероз
• ФЭГДС — фиброэзофагогастродуоденоскопия
• ХБП — хроническая болезнь почек
• ХГЧ — хорионический гонадотропин человека
• ХДН — хроническая дыхательная недостаточность
• хим. — химический
• ХНЗЛ — хронические неспецифические заболевания легких
• ХОБЛ — хроническая обструктивная болезнь легких
• ХПН — хроническая почечная недостаточность
• ХС — холестерин
• ХСН — хроническая сердечная недостаточность
• XT — химиотерапия
• ЦВД — центральное венозное давление
• ЦБК — центральный венозный катетер
• ЦИК — циркулирующие иммунные комплексы
• ЦМВ — цитомегаловирус
• ЦНС — центральная нервная система
• ЦОГ — циклооксигеназа
• ЦПД — церебральное перфузионное давление
• ЦСТС — церебральный сольтеряющий синдром
• ч — час
• ЧД — частота дыхания
• ЧДД — частота дыхательных движений
• ЧКВ — чрескожное коронарное вмешательство
• ЧМН — черепно-мозговые нервы
• ЧМТ — черепно-мозговая травма
• ЧН — черепные нервы
• ЧС — чувствительность/специфичность (ЧС 97%/87%)
• ЧСС — частота сердечных сокращений
• ЧТВ — частичное тромбопластиновое время
• ШКГ — шкала комы Глазго
• ШОП — шейный отдел позвоночника
• ЩЖ — щитовидная железа
• ЩФ — щелочная фосфатаза
• ЭАР — эквивалент активности ретинола
• ЭГДС — эзофагогастродуоденоскопия
• ЭДТА — этилендиаминтетрауксусная кислота (этилендиаминтетраацетат)
• ЭКГ — электрокардиография
• ЭКМО — экстракорпоральная мембранная оксигенация
• ЭКО — экстракорпоральное оплодотворение
• ЭКС — электрокардиостимулятор, элекгрокардиостимуляция
• ЭМГ — электромиография
• ЭМК — электронная медицинская карта
• ЭМП — экстренная медицинская помощь
• ЭНМП — экстренная и неотложная медицинская помощь
• ЭНМТ — экстремально низкая масса тела
• ЭРХПГ —эндоскопическая ретроградная холангиопанкреатография
• ЭТТ — эндотрахеальная трубка
• ЭхоКГ — эхокардиография
• ЭЭГ — электроэнцефалография
• ЮДМ — ювенильный дерматомиозит
• ЮИА — ювенильный идиопатический артрит
• ЯБ — язвенная болезнь
• АА — амилоид A (amyloid А)
• ААР — Американская академия педиатрии (American Academy of Pediatrics)
• AASLD — Американская ассоциация по изучению заболеваний печени (American Association for the Study of Liver Diseases)
• ABC — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение» (Airways-Breathing-Circulation)
• АВСАЗ — белковый член АТФ-связывающей кассеты АЗ
• АВСВ11 —ген АТФ-связывающей кассеты, 11-й член подсемейства В (ATP-binding cassette, subfamily В member 11)
• АВСВ4 — ген АТФ-связывающей кассеты, 4-й член подсемейства В (ATP-binding cassette 4 gene)
• АВСС2 — ген, кодирующий 2-й член подсемейства С АТФ-связывающих кассет (ATP-binding cassette sub-family С member 2)
• ABCDE — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение-не-врологический статус-внешний вид» (Airways-Breathing-Circulation-Disability-Exposure)
• ABCG5/G8 — гетеродимер переносчика АТФ-связывающей кассеты ABCG5 и ABCG8 (heterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
• AC — до еды (при назначениях) — ante cibum
• АСЕР — Американская коллегия врачей неотложной помощи (American College of Emergency Physicians)
• ACOG — Американская коллегия акушеров и гинекологов (American College of Obstetricians and Gynecologists)
• AHA — Американская кардиологическая ассоциация (American Heart Association)
• ALTE — очевидное опасное для жизни событие (apparent life-threatening event)
• ANP — предсердный натрийуретический пептид (atrial natriuretic peptide)
• APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
• ARPKD — аутосомно-рецессивный поликистоз почек ASCVD-риск — риск развития атеросклеротического сердечно-сосудистого заболевания (Arteriosclerotic Cardiovascular Disease)
• AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
• BCS — митохондриальный шаперон BCS1 (mitochondrial chaperone BCS1)
• BIN — биноминальная номенклатура живой природы
• B(i)PAP — режим искусственной вентиляции легких с двумя уровнями положительного давления (bilevel positive airway pressure)
• BNP — мозговой натрийуретический пептид В-типа [В (brain)-type natriuretic peptide]
• BRUE — быстро разрешившиеся необъяснимые события (brief resolved unexplained events)
• BSEP — насос выведения солей желчных кислот (bile salt export pump)
• CADASIL — церебральная аутосомно-доминантная артериопатия с подкорковыми инфарктами и лейкоэнцефалопатией (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
• CAPS — криопирин-ассоциированный периодический синдром (cryopyrin-associated periodic syndrome)
• CBIT — комплексное поведенческое воздействие при тиках (comprehensive behavioral intervention for tics)
• CD — кластеры дифференцировки (clusters of differentiation)
• CDC — Центр по контролю и профилактике заболеваний, США (Center for Disease Control and Prevention)
• CDG — врожденные нарушения гликозилирования (congenital disorder of glycosylation)
• CFTR — трансмембранный регулятор муковисцидоза (cystic fi brosis transmembrane regulator)
• CH — гемолитический комплемент (hemolytic complement)
• CLLS — шкала оценки острой горной болезни озера Луиз у детей (Children’s Lake Louise Score)
• сМОАТ — каналикулярный мультиспецифический органический анионный транспортер (canalicular multispecific organic anion transporter)
• CMT — Шарко-Мари-Тута болезнь (Charcot-Marie-Tooth disease)
• CPAP — постоянное положительное давление в дыхательных путях (constant positive airway pressure)
• CTLA — цитотоксический Т-лимфоцитарный антиген (cytotoxic T-lymphocytic antigen)
• CYP — цитохром общий
• DAF — фактор ускорения распада (decay-accelerating factor)
• DAMP — рецепторы молекулярного фрагмента, ассоциированного с повреждением (damage-associated molecular pattern)
• DASH — диетические подходы к борьбе с гипертонией (dietary approaches to stop hypertension)
• DGAT1 — диацилглицерин-1-ацилтрансфераза (diacylglycerol acyltransferase 1)
• DHR — дигидрородамин (dihydrorhodamine)
• DSM — Диагностическое и статистическое руководство по психическим расстройствам (Diagnostic and Statistical Manual of Mental Disorders)
• EAST syndrome — эпилепсия, атаксия, сенсоневральная тугоухость и тубулопатия (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
• EBM — доказательная медицина (evidance based medicine)
• EPCAM — молекула адгезии эпителиальных клеток (epithelial cell adhesion molecule)
• ESC — Европейское общество кардиологии (European Society of Cardiology)
• EXIT — лечение плода вне матки во время родов (ех utero intrapartum treatment)
• FcRs — Fc-рецепторы — белок, расположенный на поверхности нескольких видов клеток иммунной системы (естественных киллеров, макрофагов, нейтрофилов и тучных клеток) FDA — Комитет по контролю за лекарственными веществами и пищевыми добавками, США (Food and Drug Administration)
• FFR — фракционный резерв кровотока (fractional flow reserve)
• FGF-23 — фактор роста фибробластов-23 (fibroblast growth factor-23)
• FIC 1 —семейный внутрипеченочный холестаз 1-го типа, болезнь Байлера (familial intrahepatic cholestasis)
• FiO₂ — фракция кислорода (во вдыхаемом воздухе, газовой смеси)
• FISH — флуоресцентная in situ гибридизация (fluorescence in situ hybridization)
• FLAIR — восстановление инверсии с ослаблением жидкости (fluid-attenuated inversion recovery)
• FMF — семейная средиземноморская лихорадка (familial mediterranean fever)
• FODMAP — ферментируемые олиго-, ди-, моносахариды и полиолы (fermentable oligo-, di-, monosaccharides and polyols)
• FoxP3 —транскрипционный фактор семейства Forkhead Р3
• GATA — gata-связывающий белок
• DVL — трансплантат против лейкоза (graft versus leukemia)
• HADH — гидроксилацил-КоА-дегидрогеназа (Hydroxyacyl-Coenzyme A dehydrogenase)
• HAV — вирус гепатита В (hepatitis A virus)
• Hb — гемоглобин
• HBcAg — сердцевинный антиген вируса гепатита В HBeAg — антиген вируса гепатита В
• HBsAg — поверхностный антиген вируса гепатита В
• HBV — вирус гепатита В (hepatitis В virus)
• HCV — вирус гепатита С (hepatitis С virus)
• HDV — вирус гепатита D (hepatitis D virus)
• HELLP — HELLP-синдром (гемолиз, повышенный уровень печеночных ферментов, низкий уровень тромбоцитов) (hemolysis, elevated liver enzymes, low platelets)
• HEV — вирус гепатита E (hepatitis E virus)
• HFNC — назальные канюли высокого потока (heated, high-flow nasal cannula)
• Hib — гемофильная палочка типа В (Haemophilus influenzae В type)
• HLA — лейкоцитарные антигены (главного комплекса гистосовместимости) человека (human leukocyte antigens)
• HR — отношение рисков (hazard ratio)
• HRT — терапия отмены привычки (habit reversal therapy)
• Ht — гематокрит
• HTLV — Т-лимфотропный вирус человека (human T-lymphotropic virus)
• IFN — интерферон
• Ig — иммуноглобулин
• IgA — иммуноглобулин A
• IgE — иммуноглобулин E
• IgG — иммуноглобулин G
• IgM — иммуноглобулин M
• IL — интерлейкин
• IPEX — Х-сцепленный синдром иммунной дисрегуляции, полиэндокринопатии и энтеропатии (immunedysregulation polyendocrinopathy enteropathy, X-linked)
• IQ — коэффициент умственного развития (intelligence quotient)
• JAK — янус-киназа (janus kinase)
• LFA — антиген, активирующий функцию лейкоцитов (lymphocyte function-associated antigen)
• LT — лейкотриен
• MALT — лимфоидная ткань слизистой оболочки (mucosa-associated lymphoid tissue)
• MASP — МСЛ-ассоциированная сериновая протеаза (MBL-associated serine protease)
• MBL — маннозосвязывающий лектин (mannose-binding lectin)
• MCP — мембранный белок-кофактор (membrane cofactor protein)
• MDR3 — белок множественной лекарственной устойчивости 3 (multidrug resistance protein 3)
• MELAS — митохондриальная энцефалопатия, лактоацидоз и инсультоподобные эпизоды (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
• MELD — модель для оценки терминальной стадии заболеваний печени, предназначена для оценки относительной тяжести заболевания и прогноза жизни у пациентов с терминальной стадией печеночной недостаточности (ожидающих трансплантации печени) (model for end-stage liver disease)
• MERRF — миоклоническая эпилепсия с рваными красными волокнами (myoclonic epilepsy with ragged red fibers)
• MHC — главный комплекс гистосовместимости (major histocompatibility complex)
• Mr — кажущаяся молекулярная масса
• MRP — белок с множественной лекарственной устойчивостью (multidrug-resistant protein)
• MRSA — метициллинрезистентный золотистый стафилококк
• MSSA — метициллинчувствительный золотистый стафилококк
• mTOR — мишень рапамицина у млекопитающих (mammalian target of rapamycin)
• NB! — важно, обратить внимание (nota bene)
• NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
• NK — естественные клетки-киллеры (natural killer) NMDA — И-метил-В-аспартат (N-methyl-D-aspartate)
• NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (number need to treatment)
• OR — отношение шансов (odds ratio)
• paCO₂ — парциальное давление углекислого газа в артериальной крови
• PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
• PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
• PANS — острый нейропсихиатрический синдром в детском возрасте (pediatric acute-onset neuropsychiatric syndrome)
• paO₂ — парциальное давление кислорода в артериальной крови
• PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
• PC — после еды (при назначениях) (post cibum) рСО₂ — парциальное давление углекислого газа
• PCSK-9 — пропротеиновая конвертаза субтилизинкексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
• PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (periodic fevers with aphthous stomatitis, pharyngitis and adenitis)
• PFIC — семейный внутрипеченочный холестаз (familial intrahepatic cholestasis)
• Pg — простагландин
• pH — водородный показатель
• PIM — показатель летального исхода у детей (pediatric index of mortality)
• piO₂ — парциальное давление кислорода во вдыхаемом воздухе
• рО₂ — парциальное давление кислорода
• POLG — субъединица ДНК-полимеразы γ
• PRISA II — оценка риска госпитализации у детей II (pediatric risk of admission)
• PRISM — риск летального исхода у детей (pediatric risk of mortality)
• PRN — при (по) необходимости (pro re nata — при возникновении обстоятельств)
• PRSS — ген сериновой протеазы
• PS — примечание (post scriptum)
• PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
• Q#H — каждые # часов (при назначениях) (quaque... hora)
• QAM — каждое утро (при назначениях) (quaque ante meridiem)
• QPM — каждый вечер (при назначениях) (quaque post meridiem)
• RAG — ген, активирующий рекомбиназу
• RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
• RF — ревматоидный фактор
• Rh — резус(-фактор)
• Rh«-» — резус-отрицательн(ый)
• Rh«+» — резус-положительн(ый)
• ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
• ROMK — почечный наружный мозговой калиевый канал (renal outer medullary К)
• RR — относительный риск (relative risk или risk ratio)
• RW — реакция Вассермана (reaction of Wassermann)
• SaO₂ — сатурация артериальной крови кислородом
• SatO₂ — насыщение крови кислородом
• ScvO₂ — насыщение кислородом центральной венозной крови (central venous oxygen saturation)
• SD — стандартное отклонение (standart deviation)
• SFTPA — ген сурфактантного белка A
• SFTPB — ген сурфактантного белка В
• SFTPC — ген сурфактантного белка С
• SPINK — ингибитор сериновой протеазы (serine protease inhibitor kazal)
• SpO₂ — насыщение (сатурация) гемоглобина кислородом
• spp. — виды (при родовом имени микроорганизмов)
• Src. — источник информации, библиографическая ссылка (source)
• STAT1 — сигнальный преобразователь и активатор транскрипции 1 (signal transducer and activator of transcription)
• TA — Международная анатомическая терминология
• TCR — Т-клеточный рецептор (T-cell receptor)
• TIPS —трансъюгулярный внутрипеченочный портосистемный шунт; малоинвазивная хирургическая операция, проводимая под контролем рентгеноскопии (transjugular intrahepatic portosystemic shunt)
• TLR — Толл-подобный рецептор (Toll-like receptor)
• TNF — фактор некроза опухоли (tumor necrosis factor)
• TORCH — токсоплазмоз, краснуха, цитомегаловирусная инфекция, герпес и другие инфекции (toxoplasmosis, other infections, rubella, cytomegalovirus herpes simplex)
• TPM — мутация тропомиозина (mutation of the tropomyosin)
• TRAP — синдром обратной артериальной перфузии близнецов (twin reversed arterial perfusion)
• TRAPS — периодический синдром, ассоциированный с рецептором фактора некроза опухоли (tumor necrosis factor receptor-associated periodic syndrome)
• TRPM — катионный канал с транзиторным рецепторным потенциалом, подсемейство М (transient receptor potential cation channel, subfamily M)
• VEGF — фактор роста эндотелия сосудов (vascular endothelial growth factor)
• VO₂ — потребление кислорода
• WPW — синдром Вольфа-Паркинсона-Уайта (Wolff-Parkinson-White)
• XLA — Х-сцепленная агаммаглобулинемия (X-linked agammaglobulinemia)
• αDG-RD — дистрофии, связанные с α-дистрогликанами (alpha dystroglycan-related dystrophies)
• β-ХГЧ — β-субъединица хорионического гонадотропина человека

В ходе подготовки статей по сердечно-сосудистым заболеваниям в терапии для пользователей сайта МедУнивер использованы труды следующих авторов:

1. IMPROVE Trial Investigators. Comparative clinical effectiveness and cost effectiveness of endovascular strategy v open repair for ruptured abdominal aortic aneurysm: three year results of the IMPROVE randomised trial. BMJ. 2017; 359: 1–10.
2. Filardo G, Powell JT, Martinez MA, et al. Surgery for small asymptomatic abdominal aortic aneurysms. Cochrane Database Syst Rev. 2015; 2: CD001835.
3. Takagi H, Ando T, Umemoto T. Abdominal aortic aneurysm screening reduces all-cause mortality. Angiology. 2018; 69: 205–211.
4. Lederle FA, Freischlag JA, Kyriakides TC, et al. Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med. 2012; 367: 1988–1997.
5. Powell JT, Sweeting MJ, Ulug P, et al. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm OVER 5 years. Br J Surg. 2017; 104: 166–178.
6. Patel R, Sweeting MJ, Powell JT, et al. Endovascular versus open repair of abdominal aortic aneurysm in 15-years’ follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. Lancet. 2016; 388: 2366–2374.
7. Sweeting MJ, Patel R, Powell JT, et al. Endovascular repair of abdominal aortic aneurysm in patients physically ineligible for open repair: very long-term follow-up in the EVAR-2 randomized controlled trial. Ann Surg. 2017; 266: 713–719.
8. Brunkwall J, Kasprzak P, Verhoeven E, et al. Endovascular repair of acute uncomplicated aortic type B dissection promotes aortic remodelling: 1 year results of the ADSORB trial. Eur J Vasc Endovasc Surg. 2014; 48: 285–291.
9. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017; 377: 317–328.
10. Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017; 69: 837–845.
11. Stackelberg O, Wolk A, Eliasson K, et al. Lifestyle and risk of screening-detected abdominal aortic aneurysm in men. J Am Heart Assoc. 2017; 6: 1–9.
12. Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018; 67: 2–77.
13. Harky A, Kai Chan JS, Ming Wong CH, et al. Open versus endovascular repair of descending thoracic aortic aneurysm disease: a systematic review and meta-analysis. Ann Vasc Surg. 2019; 54: 304–315.
14. Aoki C, Fukuda W, Kondo N, et al. Surgical management of mycotic aortic aneurysms. Ann Vasc Dis. 2017; 10: 29–35.
15. Ying AJ, Affan ET. Abdominal aortic aneurysm screening: a systematic review and meta-analysis of efficacy and cost. Ann Vasc Surg. 2019; 54: 298–303.
16. Johansson M, Zahl PH, Siersma V et al. Benefits and harms of screening men for abdominal aortic aneurysm in Sweden: a registry-based cohort study. Lancet. 2018; 391: 2441–2447.
17. Siracuse JJ, Krafcik BM, Farber A, et al. Contemporary open repair of ruptured abdominal aortic aneurysms. J Vasc Surg. 2017; 65: 1023–1028.
18. Schermerhorn ML, Buck DB, O’Malley AJ, et al. Long-term outcomes of abdominal aortic aneurysm in the Medicare population. N Engl J Med. 2015; 373: 328–338.
19. Bennett SJ, Dill KE, Hanley M, et al. ACR appropriateness Criteria® suspected thoracic aortic aneurysm. J Am Coll Radiol. 2018; 15: S208–S214.
20. Mussa FF, Horton JD, Moridzadeh R, et al. Acute aortic dissection and intramural hematoma: a systematic review. JAMA. 2016; 316: 754–763.
21. Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: diagnosis and management, an update. Eur Heart J. 2018; 39: 739–749.
22. Alfson DB, Ham SW. Type B aortic dissections: current guidelines for treatment. Cardiol Clin. 2017; 35: 387–410.
23. Seyahi E. Takayasu arteritis: an update. Curr Opin Rheumatol. 2017; 29: 51–56.
24. Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018; 77: 348–354.
25. Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complica­tions in Takayasu arteritis: a multicenter study of 318 patients. Circulation. 2017; 136: 1114–1122.
26. Cho HJ, Bloomberg J, Nichols J. Giant cell arteritis. Dis Mon. 2017; 63: 88–91.
27. Guevara M, Kollipara CS. Recent advances in giant cell arteritis. Curr Rheumatol Rep. 2018; 20: 1–9.
28. Wright J.T. Jr, Williamson J.D., Whelton P.K., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373: 2103–2116.
29. Williamson J.D., Supiano M.A., Applegate W.B., et al. Intensive vs. standard blood pressure control and cardiovascular disease outcomes in adults aged >75 years. JAMA. 2016; 315: 2673–2682.
30. Yusuf S., Lonn E., Pais P., et al. Blood-pressure and cholesterol lowering in persons without cardio­vascular disease. N Engl J Med. 2016; 374: 2032–2043.
31. Pareek A.K., Messerli F.H., Chandurkar N.B., et al. Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol. 2016; 67: 379–389.
32. Wiysonge C.S., Bradley H.A., Volmink J., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017; 1: CD002003.
33. Bundy J.D., Li C., Stuchlik P., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017; 2: 775–781.
34. Phillips R.A., Xu J., Peterson L.E., et al. Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension. J Am Coll Cardiol. 2018; 71: 1601–1610.
35. Lonn E.M., Bosch J., Lopez-Jaramillo P., et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374: 2009–2020.
36. Berlowitz D.R., Foy C.G., Kazis L.E., et al. Effect of intensive blood-pressure treatment on patient- reported outcomes. N Engl J Med. 2017; 377: 733–744.
37. Soliman E.Z., Ambrosius W.T., Cushman W.C., et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (systolic blood pressure intervention trial). Circulation. 2017; 136: 440–450.
38. Kalkman D.N., Brouwer T.F., Vehmeijer J.T., et al. J curve in patients randomly assigned to different systolic blood pressure targets: an experimental approach to an observational paradigm. Circulation. 2017; 136: 2220–2229.
39. Brunstrom M., Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016; 352: 1–10.
40. Bangalore S., Fakheri R., Toklu B., et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016; 352: 1–12.
41. Victor R.G., Lynch K., Li N., et al. A cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med. 2018; 378: 1291–1301.
42. Williams B., MacDonald T.M., Morant S., et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015; 386: 2059–2068.
43. Kandzari D.E., Bohm M., Mahfoud F., et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018; 391: 2346–2355.
44. Azizi M., Schmieder R.E., Mahfoud F., et al. Endovascular ultrasound renal denervation to treat гипертензия (RA.DIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018; 391: 2335–2345.
45. Tsuyuki R.T., Houle S.K., Charrois T.L., et al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta clinical trial in optimizing hypertension (RxACTION). Circulation. 2015; 132: 93–100.
46. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017. ACC/AHA/AAPA/ABC/ACPM/AGS/APha/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71: 2199–2269.
47. Egan B.M., Kjeldsen S.E., Grassi G., et al. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019; 37: 1148–1153.
48. Franklin S.S., Thijs L., Asayama K., et al. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol. 2016; 68: 2033–2043.
49. Benjamin E.J., Blaha M.J., Chiuve S.E., et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017; 135: e146–e603.
50. Franklin S.S., O’Brien E., Staessen J.A. Masked hypertension: understanding its complexity. Eur Heart J. 2017; 38: 1112–1118.
51. Muntner P., Whelton P.K. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol. 2017; 69: 2446–2456.
52. Funder J.W., Carey R.M., Mantero F., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016; 101: 1889–1916.
53. Brown J.M., Robinson-Cohen C., Luque-Fernandez M.A., et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med. 2017; 167: 630–641.
54. Textor S.C. Renal arterial disease and hypertension. Med Clin North Am. 2017; 101: 65–79.
55. Reboussin D.M., Allen N.B., Griswold M.E., et al. Systematic review for the 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APha/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71: 2176–2198.
56. Cook N.R., Appel L.J., Whelton P.K. Sodium intake and all-cause mortality over 20 years in the trials of hypertension prevention. J Am Coll Cardiol. 2016; 68: 1609–1617.
57. Carey R.M., Whelton P.K. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168: 351–358.
58. Taler S.J. Initial treatment of hypertension. N Engl J Med. 2018; 378: 636–644.
59. Chamberlain J.J., Johnson E.L., Leal S., et al. Cardiovascular disease and risk management: review of the American Diabetes Association standards of medical care in diabetes 2018. Ann Intern Med. 2018; 168: 640–650.
60. Garber A.J., Abrahamson M.J., Barzilay J.I., et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract. 2017; 23: 207–238.
61. Bress A.P., Tanner R.M., Hess R., et al. Generalizability of SPRINT results to the U.S. adult population. J Am Coll Cardiol. 2016; 67: 463–472.
62. Qaseem A., Wilt T.J., Rich R., et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166: 430–437.
63. Prosser H.C.G., Azzam O., Schlaich M.P. Resistant hypertension: which agent? Heart Lung Circ. 2018; 27: 911–916.
64. Spiering W., Williams B., Van der Heyden J., et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017; 390: 2655–2661.
65. Goldberg E.M., Wilson T., Saucier C., et al. Achieving the BpTRUth: emergency department hypertension screening and the centers for Medicare & Medicaid services quality measure. J Am Soc Hypertens. 2017; 11: 290–294.
66. Fakhry F, Spronk S, van der Laan L, et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA. 2015; 314: 1936–1944.
67. Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018; 137: 338–350.
68. Pandey A, Banerjee S, Ngo C, et al. Comparative efficacy of endovascular revascularization versus supervised exercise training in patients with intermittent claudication: meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2017; 10: 712–724.
69. McDermott MM, Spring B, Berger JS, et al. Effect of a home-based exercise intervention ofwearable technology and telephone coaching on walking performance in peripheral artery disease: the HONOR randomized clinical trial. JAMA. 2018; 319: 1665–1676.
70. Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018; 71: 2306–2315.
71. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardio­vascular disease. N Engl J Med. 2017; 377: 1319–1330.
72. Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017; 376: 32–40.
73. Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016; 67: 2719–2728.
74. Bonaca MP, Creager MA, Olin J, et al. Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the T^A 2°P-TIMI 50 trial. JACC Cardiovasc Interv. 2016; 9: 2157–2164.
75. Bedenis R, Stewart M, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014; 10: CD003748.
76. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol. 2015; 65: 999–1009.
77. Goueffic Y, Della Schiava N, Thaveau F, et al. Stenting or surgery for de novo common femoral artery stenosis. JACC Cardiovasc Interv. 2017; 10: 1344–1354.
78. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial. Circulation. 2016; 133: 1472–1483.
79. Schneider PA, Laird JR, Tepe G, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018; 11: 1–8.
80. Spreen MI, Martens JM, Knippenberg B, et al. Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Am Heart Assoc. 2017; 6: 1–11.
81. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017; 135: e146–e603.
82. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; 69: 1465–1508.
83. Hamburg NM, Creager MA. Pathophysiology of intermittent claudication in peripheral artery disease. Circ J. 2017; 81: 281–289.
84. Farber A. Chronic limb-threatening ischemia. N Engl J Med. 2018; 379: 171–180.
85. Azzopardi YM, Gatt A, Chockalingam N, et al. Agreement of clinical tests for the diagnosis of peripheral arterial disease. Prim Care Diabetes. 2019; 13: 82–86.
86. Kullo IJ, Rooke TW. Clinical practice. Peripheral artery disease. N Engl J Med. 2016; 374: 861–871.
87. Kithcart AP, Beckman JA. ACC/AHA versus ESC guidelines for diagnosis and management of peripheral artery disease: JACC guideline comparison. J Am Coll Cardiol. 2018; 72: 2789–2801.
88. Ahmed O, Hanley M, Bennett SJ, et al. ACR appropriateness Criteria® vascular claudication-assessment for revascularization. J Am Coll Radiol. 2017; 14 (suppl): S372–S379.
89. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO). Eur Heart J. 2018; 39: 763–816.
90. Ramos R, Garcia-Gil M, Comas-Cufi M, et al. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. J Am Coll Cardiol. 2016; 67: 630–640.
91. Bailey SR, Beckman JA, Dao TD, et al. ACC/AHA/SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. J Am Coll Cardiol. 2019; 73: 214–237.
92. Secemsky EA, Schermerhorn M, Carroll BJ, et al. Readmissions after revascularization procedures for peripheral arterial disease: a nationwide cohort study. Ann Intern Med. 2018; 168: 93–99.
93. Hussain MA, Al-Omran M, Mamdani M, et al. Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease. JAMA Surg. 2016; 151: 742–750.
94. Cacione DG, Baptista-Silva JC, Macedo CR. Pharmacological treatment for Buerger’s disease. Cochrane Database Syst Rev. 2016; 2: CD011033.
95. Goldberg YP, Price N, Namdari R, et al. Treatment of na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012; 153: 80–85.
96. Curtiss P, Schwager Z, Cobos G, et al. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2018; 78: 1110–1118.
97. Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2017; 12: CD000467.
98. Roustit M, Giai J, Gaget O, et al. On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials. Ann Intern Med. 2018; 169: 694–703.
99. Al-Sudany NK. Treatment of primary perniosis with oral pentoxifylline (a double-blind placebo- controlled randomized therapeutic trial). Dermatol Ther. 2016; 29: 263–268.
100. Murphy M, Charlesworth J, Koh E. The effects of botulinum toxin injection in an elite sportsman with functional popliteal artery entrapment syndrome: a case report. Phys Ther Sport. 2017; 27: 7–11.
101. Li S, King BN, Velasco N, et al. Cystic adventitial disease -case series and review of literature. Ann Transl Med. 2017; 5: 1–7.
102. Motaganahalli RL, Smeds MR, Harlander-Locke MP, et al. A multi-institutional experience in adven­titial cystic disease. J Vasc Surg. 2017; 65: 157–161.
103. INSITE Collaborators. Diagnosis and management of iliac artery endofibrosis: results of a delphi consensus study. Eur J Vasc Surg. 2016; 52: 90–98.
104. Kadian-Dodov D, Gornik HL, Gu X, et al. Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U.S. Registry for FMD. J Am Coll Cardiol. 2016; 68: 176–185.
105. Lather HD, Gornik HL, Olin JW, et al. Prevalence of intracranial aneurysm in women with fibro- muscular dysplasia: a report from the US Registry for Fibromuscular Dysplasia. JAMA Neurol. 2017; 74: 1081–1087.
106. Gornik HL, Persu A, Adlam D, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019. [Epub ahead of print.]
107. Fazeli B, Dadgar Moghadam M, Niroumand S. How to treat a patient with thromboangiitis obliterans: a systematic review. Ann Vasc Surg. 2018; 49: 219–228.
108. Ra JC, Jeong EC, Kang SK, et al. A prospective, nonrandomized, no placebo-controlled, phase I/II clinical trial assessing the safety and efficacy of intramuscular injection of autologous adipose tissue-derived mesenchymal stem cells in patients with severe Buerger’s disease. Cell Med. 2017; 9: 87–102.
109. Agrawal A, Ziccardi MR, Witzke C, et al. Cholesterol embolization syndrome: an under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018; 31: 407–415.
110. Dean SM. Cutaneous manifestations of chronic vascular disease. Prog Cardiovasc Dis. 2018; 60: 567–579.
111. McDonnell A, Schulman B, Ali Z, et al. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile. Brain. 2016; 139: 1052–1065.
112. Parker LK, Ponte C, Howell KJ, et al. Clinical features and management of erythromelalgia: long term follow-up of 46 cases. Clin Exp Rheumatol. 2017; 35: 80–84.
113. Pagani-Estevez GL, Sandroni P, Davis MD, et al. Erythromelalgia: identification of a corticosteroid- responsive subset. J Am Acad Dermatol. 2017; 76: 506–511.
114. Wigley FM, Flavahan NA. Raynaud’s phenomenon. N Engl J Med. 2016; 375: 556–565.
115. Ben Salem T, Tougorti M, Bziouech S, et al. Etiological profile of secondary Raynaud’s phenomenon in an internal medicine department. About 121 patients. J Med Vasc. 2018; 43: 29–35.
116. Baker JS, Miranpuri S. Perniosis: a case report with literature review. J Am Podiatr Med Assoc. 2016; 106: 138–140.
117. Handford C, Thomas O, Imray CHE. Frostbite. EmergMed Clin North Am. 2017;35:281-299. Bergersen TK, Walloe L. Acral coldness — severely reduced blood flow to fingers and toes. Handb Clin Neurol. 2018; 157: 677–685.
118. Bova C., Bianco A., Mascaro V. et al. Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials. Thromb Res. 2016; 139: 22–28.
119. Robertson L., Yeoh S.E., Broderick C., et al. Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database Syst Rev. 2018; 11: CD010837.
120. Robin P., Le Roux P.Y., Planquette B., et al. Limited screening with versus without (18) F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol. 2016; 17: 193–199.
121. Napolitano M., Saccullo G., Malato A., et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS study. J Clin Oncol. 2014; 32: 3607–3612.
122. Ben-Aharon I., Stemmer S.M., Leibovici L., et al. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies—systematic review and meta-analysis. Acta Oncol. 2014; 53: 1230–1237.
123. Di Nisio M., Porreca E., Otten H.M., et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2014; 8: CD008500.
124. Sanford D., Naidu A., Alizadeh N., et al. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2014; 12: 1076–1085.
125. Raskob G.E., van Es N., Verhamme P., et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378: 615–624.
126. Marchioli R., Finazzi G., Specchia G., et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013; 368: 22–33.
127. Pengo V., Denas G., Zoppellaro G., et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018; 132: 1365–1371.
128. Kearon C., Ageno W., Cannegieter S.C., et al. Categorization of patients as having provoked or unpro­voked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016; 14: 1480–1483.
129. Bauer A., Nguyen-Cao T.M., Spears J.B. Issues in the diagnosis and management of hereditary antithrombin deficiency. Ann Pharmacother. 2016; 50: 758–767.
130. Pruthi R.K. Optimal utilization of thrombophilia testing. Int J Lab Hematol 2017; 39: s104–s110.
131. Connors J.M. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017; 377: 1177–1187.
132. Falanga A., Russo L., Milesi V., et al. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017; 118: 79–83.
133. van Es N., Le Gal G., Otten H.M., et al. Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med. 2017; 167: 410–417.
134. Husseinzadeh H., Carrier M. Occult cancer detection in patients with hemostatic disorder and venous thromboembolism. Thromb Res. 2018; 163: 242–245.
135. Frere C., Benzidia I., Marjanovic Z., et al. Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges. Cancers (Basel). 2019; 1–17.
136. Patriquin C.J., Kiss T., Caplan S., et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. Eur J Haematol. 2019; 102: 36–52.
137. Garcia D., Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018; 378: 2010–2021.
138. Kato M., Hisada R., Atsumi T. Clinical profiles and risk assessment in patients with antiphospholipid antibodies. Expert Rev Clin Immunol. 2019; 15: 73–81.
139. Dufrost V., Risse J., Zuily S., et al. Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep. 2016; 18: 1–8.
140. Gebhart J., Posch F., Koder S., et al. Increased mortality in patients with the lupus anticoagulant: the Vienna lupus anticoagulant and thrombosis study (LATS). Blood. 2015; 125: 3477–3483.
141. Kearon C., Parpia S., Spencer F.A., et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018; 131: 2151–2160.
142. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017; 107: 43–51.
143. Pickar J.H., Archer D.F., Kagan R., et al. Safety and benefit considerations for menopausal hormone therapy. Expert Opin Drug Saf. 2017; 16: 941–954.
144. Gordon R.J., Lombard F.W. Perioperative venous thromboembolism: a review. Anesth Analg. 2017; 125: 403–412.
145. Zondag W., Kooiman J., Klok F.A., et al. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J. 2013; 42: 134–144.
146. Meyer G., Vicaut E., Danays T., et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014; 370: 1402–1411.
147. Sterne J.A., Bodalia P.N., Bryden P.A., et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017; 21: 1–386.
148. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808.
149. Prins M.H., Lensing A.W., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11: 1–10.
150. Schulman S., Kakkar A.K., Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764–772.
151. Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–1415.
152. Vedantham S., Goldhaber S.Z., Julian J.A., et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017; 377: 2240–2252.
153. Carrier M., Lazo-Langner A., Shivakumar S., et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015; 373: 697–704.
154. Robin P., Le Roux P.Y., Planquette B., et al. Limited screening with versus without 18f-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol. 2016; 17: 193–199.
155. Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699–708.
156. Weitz J.I., Lensing A.W.A., Prins M.H., et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017; 376: 1211–1222.
157. Mismetti P., Laporte S., Pellerin O., et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA. 2015; 313: 1627–1635.
158. Carrier M., Cameron C., Delluc A., et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014; 134: 1214–1219.
159. Raskob G.E., van Es N., Verhamme P., et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378: 615–624.
160. Young A.M., Marshall A., Thirlwall J., et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36: 2017–2023.
161. Kahn S.R., Shapiro S., Wells P.S., et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet. 2014; 383: 880–888.
162. Gohel M.S., Heatley F., Liu X., et al. A randomized trial of early endovenous ablation in venous ulceration. N Engl J Med. 2018; 378: 2105–2114.
163. Ghofrani H.A., DArmini A.M., Grimminger F., et al. Riociguat for the treatment of chronic throm­boembolic pulmonary hypertension. N Engl J Med. 2013; 369: 319–329.
164. Beyer-Westendorf J., Schellong S.M., Gerlach H., et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017; 4: e105-e113.
165. Cohen A.T., Harrington A., Goldhaber S.Z., et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016; 375: 534–544.
166. Heit J.A., Spencer F.A., White R.H. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016; 41: 3–14.
167. Di Nisio M., van Es N., Buller H.R. Deep vein thrombosis and pulmonary embolism. Lancet. 2016; 388: 3060–3073.
168. Connors J.M. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017; 377: 1177–1187.
169. Wells P.S., Ihaddadene R., Reilly A., et al. Diagnosis of venous thromboembolism: 20 years of progress. Ann Intern Med. 2018; 168: 131–140.
170. Weitz J.I., Fredenburgh J.C., Eikelboom J.W. A test in context: D-dimer. J Am Coll Cardiol. 2017; 70: 2411–2420.
171. Hess S., Madsen P.H. Radionuclide diagnosis of pulmonary embolism. Adv Exp Med Biol. 2017; 906: 49–65.
172. Curtis B.R., Cox M., Poplawski M., et al. Low yield of ventilation and perfusion imaging for the evaluation of pulmonary embolism after indeterminate CT pulmonary angiography. EmergRadiol. 2017; 24: 525–530.
173. Benson D.G., Schiebler M.L., Nagle S.K., et al. Magnetic resonance imaging for the evaluation of pulmonary embolism. Top Magn Reson Imaging. 2017; 26: 145–151.
174. Tritschler T., Kraaijpoel N., Le Gal G., et al. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018; 320: 1583–1594.
175. Ghazvinian R., Gottsater A., Elf J.L. Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism. J Thromb Thrombolysis. 2018; 45: 319–324.
176. van Es N., Le Gal G., Otten H.M., et al. Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med. 2017; 167: 410–417.
177. Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016; 149: 315–352.
178. Prandoni P., Vedovetto V., Ciammaichella M., et al. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis. Thromb Res. 2017; 154: 35–41.
179. Rodger M.A., Le Gal G., Anderson D.R., et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017; 356: 1–10.
180. Pollack C.V. Jr, Reilly P.A., van Ryn J., et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017; 377: 431–441.
181. Connolly S.J., Milling T.J. Jr, Eikelboom J.W., et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016; 375: 1131–1141.
182. Bikdeli B., Chatterjee S., Desai N.R., et al. Inferior vena cava filters to prevent pulmonary embolism: systematic review and meta-analysis. J Am Coll Cardiol. 2017; 70: 1587–1597.
183. Frere C., Benzidia I., Marjanovic Z., et al. Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges. Cancers (Basel). 2019; 11: 1–17.
184. Villani M., Ageno W., Grandone E., et al. The prevention and treatment of venous thromboembolism in pregnancy. Expert Rev Cardiovasc Ther. 2017; 15: 397–402.
185. Winter M.P., Schernthaner G.H., Lang I.M. Chronic complications of venous thromboembolism. J Thromb Haemost. 2017; 15: 1531–1540.
186. Mahmud E., Madani M.M., Kim N.H., et al. Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease. J Am Coll Cardiol. 2018; 71: 2468–2486.
187. Shatzel J.J., O’Donnell M., Olson S.R., et al. Venous thrombosis in unusual sites: a practical review for the hematologist. Eur J Haematol. 2019; 102: 53–62.
188. Chang S.L., Huang Y.L., Lee M.C., et al. Association of varicose veins with incident venous thrombo­embolism and peripheral artery disease. JAMA. 2018; 319: 807–817.
189. Newbigin K., Souza C.A., Torres C., et al. Fat embolism syndrome: state-of-the-art review focused on pulmonary imaging findings. Respir Med. 2016; 113: 93–100.
190. Brull S.J., Prielipp R.C. Vascular air embolism: a silent hazard to patient safety. J Crit Care. 2017; 42: 255–263.
191. Bonnet M.P., Zlotnik D., Saucedo M., et al. Maternal death due to amniotic fluid embolism: a national study in France. Anesth Analg. 2018; 126: 175–182.
192. Judge C., Mello S., Bradley D., et al. A systematic review of the causes and management of ischaemic stroke caused by nontissue emboli. Stroke Res Treat. 2017; 2017: 1–8.
193. Hutchinson J.C., Fulcher J.W., Hanna J., et al. Pulmonary tumor thrombotic microangiopathy: case report and review of literature. Am J Forensic Med Pathol. 2018; 39: 56–60.
194. Ehlken N, Lichtblau M, Klose H, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J. 2016; 37: 35–44.
195. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013; 127: 624–633.
196. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015; 373: 2522–2533.
197. Igarashi A, Inoue S, Ishii T, et al. Comparative effectiveness of oral medications for pulmonary arterial hypertension. Int Heart J. 2016; 57: 466–472.
198. Jain S, Khera R, Girotra S, et al. Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis. Chest. 2017; 151: 90–105.
199. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369: 809–818.
200. Barnes H, Brown Z, Burns A, et al. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019; 1: CD012621.
201. Zhao R, Jiang Y. Influence of riociguat treatment on pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Herz. 2018. [Epub ahead of print.]
202. Lajoie AC, Lauziere G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016; 4: 291–305.
203. Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015; 373: 834–844.
204. Ghofrani HA, DArmini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369: 319–329.
205. Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med. 2017; 141: 696–703.
206. Kato M, Atsumi T. Pulmonary arterial hypertension associated with connective tissue diseases: a review focusing on distinctive clinical aspects. Eur J Clin Invest. 2018; 48: 1–9.
207. Balko R, Edriss H, Nugent K, et al. Pulmonary veno-occlusive disease: an important consideration in patients with pulmonary hypertension. Respir Med. 2017; 132: 203–209.
208. Ramu B, Houston BA, Tedford RJ. Pulmonary vascular disease: hemodynamic assessment and treatment selection—focus on group II pulmonary hypertension. Curr Heart Fail Rep. 2018; 15: 81–93.
209. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37: 67–119.
210. Kharat A, Hachulla AL, Noble S, et al. Modern diagnosis of chronic thromboembolic pulmonary hypertension. Thromb Res. 2018; 163: 260–265.
211. Bazan IS, Mensah KA, Rudkovskaia AA, et al. Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: a review. Respir Med. 2018; 134: 42–46.
212. Klinger JR, Elliott G, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults 2018: update of the CHEST Guideline and Expert Panel Report. Chest. 2019. [Epub ahead of print.] Bhogal S, Mukherjee D, Banerjee S, et al. Current trends and future perspectives in the treatment of pulmonary arterial hypertension. Curr Probl Cardiol. 2018; 43: 191–216.
213. Mahmud E, Madani MM, Kim NH, et al. Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease. J Am Coll Cardiol. 2018; 71: 2468–2486.
214. Mahmud E, Madani MM, Kim NH, et al. Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease. J Am Coll Cardiol. 2018; 71: 2468–2486.
215. Mahmud E, Behnamfar O, Ang L, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin. 2018; 7: 103–117.
216. McLaughlin VV, Hoeper MM, Channick RN, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol. 2018; 71: 752–763.
217. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50: 1–10.
218. Belley-Cote E.P., Hanif H., DAragon F., et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. Thromb Haemost. 2015; 114: 768–777.
219. Hakoum M.B., Kahale L.A., Tsolakian I.G., et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018; 1: CD006649.
220. Li A., Garcia D.A., Lyman G.H., et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019; 173: 158–163.
221. Brandao G.M., Junqueira D.R., Rollo H.A., et al. Pentasaccharides for the treatment of deep vein thrombosis. Cochrane Database Syst Rev. 2017; 12: CD011782.
222. Eikelboom J.W., Connolly S.J., Bosch J., et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319–1330.
223. Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287–1297.
224. Weitz J.I., Lensing A.W.A., Prins M.H., et al. Rivaroxaban or aspirin for extended treatment ofvenous thromboembolism. N Engl J Med. 2017; 376: 1211–1222.
225. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808.
226. Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699–708.
227. Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–1415.
228. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093–2104.
229. Goette A., Merino J.L., Ezekowitz M.D., et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016; 388: 1995–2003.
230. Cohen A.T., Harrington R.A., Goldhaber S.Z., et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016; 375: 534–544.
231. Bruins Slot K.M., Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2018; 3: CD008980.
232. Sterne J.A., Bodalia P.N., Bryden P.A., et al. Oral anticoagulants for primary prevention, treatment and secondary prevention ofvenous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017; 21: 1–386.
233. Sharma M., Cornelius V.R., Patel J.P., et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015; 132: 194–204.
234. Raskob G.E., van Es N., Verhamme P., et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378: 615–624.
235. Meyer G., Vicaut E., Danays T., et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014; 370: 1402–1411.
236. Zheng S.L., Roddick A.J. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019; 321: 277–287.
237. Bowman L., Mafham M., Wallendszus K., et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018; 379: 1529–1539.
238. McNeil J.J., Nelson M.R., Woods R.L., et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018; 379: 1519–1528.
239. Sharma A., Hai O., Garg A., et al. Duration of dual antiplatelet therapy following drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2017; 42: 404–417.
240. Raheja H., Garg A., Goel S., et al. Comparison of single versus dual antiplatelet therapy after TAVR: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2018; 92: 783–791.
241. Vestergaard A.S., Skj0th F., Larsen T.B., et al. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS ONE. 2017; 12: 1–17.
242. Karimi K., Odhav A., Kollipara R., et al. Acute cutaneous necrosis: a guide to early diagnosis and treatment. J Cutan Med Surg. 2017; 21: 425–437.
243. Shen Y.M., Wolfe H., Barman S. Evaluating thrombocytopenia during heparin therapy. JAMA. 2018; 319: 497–498.
244. Zeitouni M., Kerneis M., Nafee T., et al. Anticoagulation in acute coronary syndrome—state of the art. Prog Cardiovasc Dis. 2018; 60: 508–513.
245. Mumoli N., Mastroiacovo D., Tamborini-Permunian E., et al. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. J Cardiovasc Med (Hagerstown). 2017; 18: 467–477.
246. Calkins H., Willems S., Gerstenfeld E.P., et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017; 376: 1627–1636.
247. Pollack C.V. Jr, Reilly P.A., van Ryn J., et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017; 377: 431–441.
248. Tornkvist M., Smith J.G., Labaf A. Current evidence of oral anticoagulant reversal: a systematic review. Thromb Res. 2018; 162: 22–31.
249. Powers W.J., Rabinstein A.A., Ackerson T., et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018; 49: e46–e110.
250. McFadyen J.D., Schaff M., Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018; 15: 181–191.
251. Patrono C., Morais J., Baigent C., et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol. 2017; 70: 1760–1776.
252. Rothwell P.M., Cook N.R., Gaziano J.M., et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018; 392: 387–399.
253. Levine G.N., Bates E.R., Bittl J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016; 68: 1082–1115.
254. Guirguis-Blake J.M., Evans C.V., Senger C.A., et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016; 164: 804–813.
255. Valgimigli M., Bueno H., Byrne R.A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39: 213–260.
256. Vos C.G., Vahl A. Anticoagulation and antiplatelet therapy in patients with peripheral arterial disease of the femoro-popliteal arteries. J Cardiovasc Surg (Torino). 2018; 59: 164–171.
257. Michelson A.D., Bhatt D.L. How I use laboratory monitoring of antiplatelet therapy. Blood.
258. Gerhard-Herman M.D., Gornik H.L., Barrett C., et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; 69: e71–e126.
259. Tsigkou V., Siasos G., Rovos K., et al. Peripheral artery disease and antiplatelet treatment. Curr Opin Pharmacol. 2018; 39: 43–52.
260. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018; 379: 250–259.
261. Gotberg M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med. 2017; 376: 1813–1823.
262. Sabate M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 2016; 387: 357–366.
263. Bonaa KH, Mannsverk J, Wiseth R, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016; 375: 1242–1252.
264. Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018; 391: 1274–1284.
265. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377: 1513–1524.
266. Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017; 390: 760–772.
267. Kereiakes DJ, Yeh RW, Massaro JM, et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015; 313: 1113–1121.
268. Sedlis SP, Hartigan PM, Teo KK, et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015; 373: 1937–1946.
269. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018; 391: 31–40.
270. Taggart DP, Altman DG, Gray AM, et al. Randomized trial of bilateral versus single internal-thoracicartery grafts. N Engl J Med. 2016; 375: 2540–2549.
271. Gaudino M, Benedetto U, Fremes S, et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. N Engl J Med. 2018; 378: 2069–2077.
272. Smart NA, Dieberg G, King N. Long-term outcomes of on- versus off-pump coronary artery bypass grafting. J Am Coll Cardiol. 2018; 71: 983–991.
273. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016; 374: 1511–1520.
274. Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018; 391: 939–948.
275. Giacoppo D, Colleran R, Cassese S, et al. Percutaneous coronary intervention vs coronary artery bypass grafting in patients with left main coronary artery stenosis: a systematic review and metaanalysis. JAMA Cardiol. 2017; 2: 1079–1088.
276. Mancini GB, Farkouh ME, Brooks MM, et al. Medical treatment and revascularization options in patients with type 2 diabetes and coronary disease. J Am Coll Cardiol. 2016; 68: 985–995.
277. Schmidt T, Abbott JD. Coronary stents: history, design, and construction. J Clin Med. 2018; 7: 1–8.
278. Crea F, Bairey Merz CN, Beltrame JF, et al. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. 2019. [Epub ahead of print.]
279. Gulizia MM, Colivicchi F, Abrignani MG, et al. Consensus document ANMCO/ANCE/ARCA/ GICR-IACPR/GISE/SICOA: long-term antiplatelet therapy in patients with coronary artery disease. Eur Heart J Suppl. 2018; 20: F1–F74.
280. Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015; 373: 2038–2047.
281. Cuisset T, Verheugt FWA, Mauri L. Update on antithrombotic therapy after percutaneous coronary revascularisation. Lancet. 2017; 390: 810–820.
282. Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med. 2017; 376: 2053–2064.
283. Head SJ, Milojevic M, Taggart DP, et al. Current practice of state-of-the-art surgical coronary revascularization. Circulation. 2017; 136: 1331–1345.
284. Alexander JH, Smith PK. Coronary-artery bypass grafting. N Engl J Med. 2016; 374: 1954–1964.
285. Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 appropriate use criteria for coronary revascularization in patients with acute coronary syndromes: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2017; 69: 570–591.
286. Ruel M, Falk V, Farkouh ME, et al. Myocardial revascularization trials. Circulation. 2018; 138: 2943–2951.
287. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate risk patients. N Engl J Med. 2016; 374: 1609–1620.
288. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017; 376: 1321–1331.
289. Lazkani M, Singh N, Howe C, et al. An updated meta-analysis of TAVR in patients at intermediate risk for SAVR. Cardiovasc Revasc Med. 2019; 20: 57–69.
290. Wang Y, Zhou Y, Zhang L, et al. Midterm outcome of transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: a meta-analysis of randomized controlled trials. J Cardiol. 2018; 71: 534–539.
291. Michler RE, Smith PK, Parides MK, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2016; 374: 1932–1941.
292. Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med. 2016; 374: 344–353.
293. Virk SA, Tian DH, Sriravindrarajah A, et al. Mitral valve surgery and coronary artery bypass grafting for moderate-to-severe ischemic mitral regurgitation: meta-analysis of clinical and echocardiographic outcomes. J Thorac Cardiovasc Surg. 2017; 154: 127–136.
294. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018; 379: 2297–2306.
295. Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015; 66: 2844–2854.
296. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018; 379: 2307–2318.
297. Bakaeen FG, Rosengart TK, Carabello BA. Aortic stenosis. Ann Intern Med. 2017; 166: ITC1–ITC16.
298. Redfors B, Pibarot P, Gillam LD, et al. Stress testing in asymptomatic aortic stenosis. Circulation. 2017; 135: 1956–1976.
299. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135: e1159–e1195.
300. Tastet L, Enriquez-Sarano M, Capoulade R, et al. Impact of aortic valve calcification and sex on hemodynamic progression and clinical outcomes in AS. J Am Coll Cardiol. 2017; 69: 2096–2098.
301. Bonow RO, Brown AS, Gillam LD, et al. ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/ SCMR/STS 2017 appropriate use criteria for the treatment of patients with severe aortic stenosis: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Valve Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2017; 70: 2566–2598.
302. Gonoreux P, Pibarot P, Redfors B, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J. 2017; 38: 3351–3358.
303. Remenyi B, ElGuindy A, Smith SC Jr, et al. Valvular aspects of rheumatic heart disease. Lancet. 2016; 387: 1335–1346.
304. Banovic M, DaCosta M. Degenerative mitral stenosis: from pathophysiology to challenging interventional treatment. Curr Probl Cardiol. 2019; 44: 10–35.
305. Carabello BA. A tragedy of modern cardiology: using ejection fraction to gauge left ventricular function in mitral regurgitation. Heart. 2017; 103: 570–571.
306. O’Gara PT, Grayburn PA, Badhwar V, et al. 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017; 70: 2421–2449.
307. Lazam S, Vanoverschelde JL, Tribouilloy C, et al. Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry. Circulation. 2017; 135: 410–422.
308. Guerrero M, Urena M, Himbert D, et al. 1-year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Am Coll Cardiol. 2018; 71: 1841–1853.
309. Praz F, Spargias K, Chrissoheris M, et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet. 2017; 390: 773–780.
310. Dziadzko V, Clavel MA, Dziadzko M, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018; 391: 960–969.
311. Delling FN, Rong J, Larson MG, et al. Evolution of mitral valve prolapse: insights from the Framingham Heart Study. Circulation. 2016; 133: 1688–1695.
312. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015; 65: 1231–1248.
313. Mentias A, Feng K, Alashi A, et al. Long-term outcomes in patients with aortic regurgitation and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2016; 68: 2144–2153.
314. Arsalan M, Walther T, Smith RL 2nd, et al. Tricuspid regurgitation diagnosis and treatment. Eur Heart J. 2017; 38: 634–638.
315. Hahn RT, Meduri CU, Davidson CJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol. 2017; 69: 1795–1806.
316. Um KJ, McClure GR, Belley-Cote EP, et al. Hemodynamic outcomes of the Ross procedure versus other aortic valve replacement: a systematic review and meta-analysis. J Cardiovasc Surg (Torino). 2018; 59: 462–470.
317. Head SJ, ?elik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017; 38: 2183–2191.
318. Goldstone AB, Chiu P, Baiocchi M, et al. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N Engl J Med. 2017; 377: 1847–1857.
319. Marti-Carvajal AJ, Dayer M, Conterno LO, et al. A comparison of different antibiotic regimens for the treatment of infective endocarditis. Cochrane Database Syst Rev. 2016; 4: CD009880.
320. Kang DH, Kim YJ, Kim SH, et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 2012; 366: 2466–2473.
321. Limeres Posse J, Alvarez Fernandez M, Fernandez Feijoo J, et al. Intravenous amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial. J Antimicrob Chemother. 2016; 71: 2022–2030.
322. Krahn AD, Longtin Y, Philippon F, et al. Prevention of arrhythmia device infection trial: the PADIT trial. J Am Coll Cardiol. 2018; 72: 3098–3109.
323. Schranz AJ, Fleischauer A, Chu VH, et al. Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data. Ann Intern Med. 2019; 170: 31–40.
324. Toyoda N, Chikwe J, Itagaki S, et al. Trends in infective endocarditis in California and New York State, 1998–2013. JAMA. 2017; 317: 1652–1660.
325. Ozcan C, Raunso J, Lamberts M, et al. Infective endocarditis and risk of death after cardiac implantable electronic device implantation: a nationwide cohort study. Europace. 2017; 19: 1007–1014.
326. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015; 132: 1435–1486.
327. Choi HN, Park KH, Park S, et al. Prosthetic valve endocarditis caused by HACEK organisms: a case report and systematic review of the literature. Infect Chemother. 2017; 49: 282–285.
328. Mohananey D, Mohadjer A, Pettersson G, et al. Association of vegetation size with embolic risk in patients with infective endocarditis: a systematic review and meta-analysis. JAMA Intern Med. 2018; 178: 502–510.
329. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016; 387: 882–893.
330. Cahill TJ, Baddour LM, Habib G, et al. Challenges in infective endocarditis. J Am Coll Cardiol. 2017; 69: 325–344.
331. Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis: a review. JAMA. 2018; 320: 72–83.
332. Anantha Narayanan M, Mahfood Haddad T, Kalil AC, et al. Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis. Heart. 2016; 102: 950–957.
333. Pettersson GB, Coselli JS, Hussain ST, et al. 2016 the American Association for Thoracic Surgery (AATS) consensus guidelines: surgical treatment of infective endocarditis: executive summary. J Thorac Cardiovasc Surg. 2017; 153: 1241–1258.
334. Sandoe JA, Barlow G, Chambers JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint working party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother. 2015; 70: 325–359.
335. Tan EM, DeSimone DC, Sohail MR, et al. Outcomes in patients with cardiovascular implantable electronic device infection managed with chronic antibiotic suppression. Clin Infect Dis. 2017; 64: 1516–1521.
336. Thornhill MH, Gibson TB, Cutler E, et al. Antibiotic prophylaxis and incidence of endocarditis before and after the 2007 AHA recommendations. J Am Coll Cardiol. 2018; 72: 2443–2454.
337. Cahill TJ, Harrison JL, Jewell P, et al. Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis. Heart. 2017; 103: 937–944.
338. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013; 369: 1522–1528.
339. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014; 383: 2232–2237.
340. Li YL, Qiao SB, Wang JY, et al. Colchicine in addition to conventional therapy for pericarditis recurrence: an update meta-analysis. Herz. 2016; 41: 630–638.
341. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016; 316: 1906–1912.
342. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COP-2 randomized clinical trial. JAMA. 2014; 312: 1016–1023.
343. Wiysonge CS, Ntsekhe M, Thabane L, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017; 9: CD000526.
344. Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. JAMA. 2015; 314: 1498–1506.
345. Farzad A, Schussler JM. Acute myopericardial syndromes. Cardiol Clin. 2018; 36: 103–114.
346. Gouriet F, Levy PY, Casalta JP, et al. Etiology of pericarditis in a prospective cohort of 1162 cases. Am J Med. 2015; 128: 784.e1–784.e8.
347. Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial disease. Eur Heart J. 2015; 36: 2921–2964.
348. Lazaros G, Imazio M, Brucato A, et al. The role of colchicine in pericardial syndromes. Curr Pharm Des. 2018; 24: 702–709.
349. Imazio M, Lazaaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovascu Med. 2016; 17: 263–269.
350. Johnston DR. Surgical management of pericardial diseases. Prog Cardiovasc Dis. 2017; 59: 407–416.
351. Hoit BD. Pericardial effusion and cardiac tamponade in the new millennium. Curr Cardiol Rep. 2017; 19: 1–11.
352. Imazio M, Gaido L, Battaglia A, et al. Contemporary management of pericardial effusion: practical aspects for clinical practice. Postgrad Med. 2017; 129: 178–186.
353. Welch TD. Constrictive pericarditis: diagnosis, management and clinical outcomes. Heart. 2018; 104: 725–731.
354. Miranda WR, Oh JK. Constrictive pericarditis: a practical clinical approach. Prog Cardiovasc Dis. 2017; 59: 369–379.
355. Ak K, Demirbas E, Atas H, et al. Results of pericardiectomy for constrictive pericarditis: single-center experience. Herz. 2017; 42: 75–83.
356. Kim KH, Miranda WR, Sinak LJ, et al. Effusive-constrictive pericarditis after pericardiocentesis: incidence, associated findings, and natural history. JACC Cardiovasc Imaging. 2018; 11: 534–541.
357. El Haddad D, Iliescu C, Yusuf SW, et al. Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. J Am Coll Cardiol. 2015; 66: 1119–1128.
358. Alkharabsheh S, Gentry III JL, Khayata M, et al. Clinical features, natural history, and management of pericardial cysts. Am J Cardiol. 2019; 123: 159–163.
359. Villablanca PA, Briston DA, Rodes-Cabau J, et al. Treatment options for the closure of secundum atrial septal defects: a systematic review and meta-analysis. Int J Cardiol. 2017; 241: 149–155.
360. Sandergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377: 1033–1042.
361. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377: 1022–1032.
362. Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377: 1011–1021.
363. Yang J, Yang L, Yu S, et al. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: a randomized controlled trial. J Am Coll Cardiol. 2014; 63: 1159–1168.
364. Gilboa SM, Devine OJ, Kucik JE, et al. Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation. 2016; 134: 101–109.
365. O’Byrne ML, Levi DS. State-of-the-art atrial septal defect closure devices for congenital heart. Interv Cardiol Clin. 2019; 8: 11–21.
366. Coughlan JJ, Daly A, Arnous S, et al. Patent foramen ovale and cryptogenic stroke: contemporary evidence and treatment. Expert Rev Cardiovasc Ther. 2018; 16: 27–37.
367. Shovlin CL, Condliffe R, Donaldson JW, et al. British Thoracic Society clinical statement on pulmonary arteriovenous malformations. Thorax. 2017; 72: 1154–1163.
368. Dijkema EJ, Leiner T, Grotenhuis HB. Diagnosis, imaging and clinical management of aortic coarctation. Heart. 2017; 103: 1148–1155.
369. Smith CA, McCracken C, Thomas AS, et al. Long-term outcomes of tetralogy of Fallot: a study from the Pediatric Cardiac Care Consortium. JAMA Cardiol. 2019; 4: 34–41.
370. Safi LM, Bhatt AB. Update on the management of adults with arterial switch procedure for transposition of the great arteries. Curr Treat Options Cardiovasc Med. 2017; 19: 1–6.
371. Shi G, Zhu Z, Chen J, et al. Total anomalous pulmonary venous connection: the current management strategies in a pediatric cohort of 768 patients. Circulation. 2017; 135: 48–58.
372. Ntiloudi D, Zanos S, Gatzoulis MA, et al. How to evaluate patients with congenital heart diseaserelated pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2019; 17: 11–18.
373. Oliver JM, Gallego P, Gonzalez AE, et al. Risk factors for excess mortality in adults with congenital heart diseases. Eur Heart J. 2017; 38: 1233–1241.
374. Hayward RM, Foster E, Tseng ZH. Maternal and fetal outcomes of admission for delivery in women with congenital heart disease. JAMA Cardiol. 2017; 2: 664–671.
375. Marelli A, Miller SP, Marino BS, et al. Brain in congenital heart disease across the lifespan: the cumulative burden of injury. Circulation. 2016; 133: 1951–1962.
376. Douglas P.S., Hoffmann U., Patel M.R., et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015; 372: 1291–1300.
377. Mark D.B., Anstrom K.J., Sheng S., et al. Quality-of-life outcomes with anatomic versus functional diagnostic testing strategies in symptomatic patients with suspected coronary artery disease: results from the PROMISE randomized trial. Circulation. 2016; 133: 1995–2007.
378. Hoffmann U., Ferencik M., Udelson J.E., et al. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (prospective multicenter imaging study for evaluation of chest pain). Circulation. 2017; 135: 2320–2332.
379. Budoff M.J, Mayrhofer T., Ferencik M., et al. Prognostic value of coronary artery calcium in the PROMISE study (prospective multicenter imaging study for evaluation of chest pain). Circulation. 2017; 136: 1993–2005.
380. Zimmermann F.M., Omerovic E., Fournier S., et al. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J. 2019; 40: 180–186.
381. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387–2397.
382. Karatasakis A., Danek B.A., Karacsonyi J., et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017; 6: 1–13.
383. Bhatt D.L., Steg P.G., Miller M., REDUCE-IT Investigators, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380: 11–22.
384. Bangalore S., Fakheri R., Wandel S., et al. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ. 2017; 356: 1–10.
385. Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791–1800.
386. Connolly S.J., Eikelboom J.W., Bosch J., et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391: 205–218.
387. Eikelboom J.W., Connolly S.J., Bosch J., et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319–1330.
388. Salazar C.A., Basilio Flores J.E., Veramendi Espinoza L.E., et al. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev. 2017; 2: CD011747.
389. Ridker P.M., Everett B.M., Thuren T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377: 1119–1131.
390. Ridker P.M., Everett B.M., Pradhan A., CIRT Investigators, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019; 380: 752–762.
391. Sedlis S.P., Hartigan P.M., Teo K.K., et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015; 373: 1937–1946.
392. Al-Lamee R., Thompson D., Dehbi H.M., et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018; 391: 31–40.
393. Werner G.S., Martin-Yuste V., Hildick-Smith D., et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018; 39: 2484–2493.
394. Mohr F.W., Morice M.C., Kappetein A.P., et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013; 381: 629–638.
395. Farkouh M.E., Domanski M., Sleeper L.A., et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012; 367: 2375–2384.
396. Mancini G.B.J., Boden W.E., Brooks M.M., et al. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials. Atherosclerosis. 2018; 277: 186–194.
397. Long L., Anderson L., Dewhirst A.M., et al. Exercise-based cardiac rehabilitation for adults with stable angina. Cochrane Database Syst Rev. 2018; 2: CD012786.
398. Benjamin E.J., Virani S.S., Callaway C.W., et al. Heart disease and stroke statistics—2018 update: a report from the American heart association. Circulation. 2018; 137: e67–e492.
399. Roth G.A., Johnson C., Abajobir A., et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70: 1–25.
400. Ohman E.M. Clinical practice. Chronic stable angina. N Engl J Med. 2016; 374: 1167–1176.
401. Lindholm D., Lindback J., Armstrong P.W., et al. Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease. J Am Coll Cardiol. 2017; 70: 813–826.
402. Ladapo J.A., Budoff M.J., Sharp D., et al. Utility of a precision medicine test in elderly adults with symptoms suggestive of coronary artery disease. J Am Geriatr Soc. 2018; 66: 309–315.
403. Knuuti J., Ballo H., Juarez-Orozco L.E., et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J. 2018; 39: 3322–3330.
404. Mittal T.K., Pottle A., Nicol E., et al. Prevalence of obstructive coronary artery disease and prognosis in patients with stable symptoms and a zero-coronary calcium score. Eur Heart J Cardiovasc Imaging. 2017; 18: 922–929.
405. Moss A.J., Williams M.C., Newby D.E., et al. The updated NICE guidelines: cardiac CT as the first-line test for coronary artery disease. Curr Cardiovasc Imaging Rep. 2017; 10: 1–7.
406. Rousan T.A., Mathew S.T., Thadani U. Drug therapy for stable angina pectoris. Drugs. 2017; 77: 265–284.
407. White C.M., Weeda E.R., Nguyen E. Should an LDL-cholesterol target-based approach be readopted? Ann Pharmacother. 2018; 52: 175–184.
408. Valgimigli M., Bueno H., Byrne R.A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39: 213–260.
409. Padala S.K., Lavelle M.P., Sidhu M.S., et al. Antianginal therapy for stable ischemic heart disease: a contemporary review. J Cardiovasc Pharmacol Ther. 2017; 22: 499–510.
410. Ferrari R., Pavasini R., Camici P.G., et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019; 40: 190–194.
411. Divakaran S., Loscalzo J. The role of nitroglycerin and other nitrogen oxides in cardiovascular therapeutics. J Am Coll Cardiol. 2017; 70: 2393–2410.
412. Patel A.V., Bangalore S. Challenges with evidence-based management of stable ischemic heart disease. Curr Cardiol Rep. 2017; 19: 1–9.
413. Al-Lamee R.K., Nowbar A.N., Francis D.P. Percutaneous coronary intervention for stable coronary artery disease. Heart. 2019; 105: 11–19.
414. Liu A., Wijesurendra R.S., Liu J.M, et al. Gadolinium-free cardiac MR stress T1-mapping to distinguish epicardial from microvascular coronary disease. J Am Coll Cardiol. 2018; 71: 957–968.
415. Ouellette M.L., Loffler A.I., Beller G.A., et al. Clinical characteristics, sex differences, and outcomes in patients with normal or near-normal coronary arteries, non-obstructive or obstructive coronary artery disease. J Am Heart Assoc. 2018; 7: 1–13.
416. Shah A.S.V., Anand A., Strachan F.E., et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet. 2018; 392: 919–928.
417. Siontis G.C., Mavridis D., Greenwood J.P., et al. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ. 2018; 360: 1–14.
418. Jobs A., Mehta S.R., Montalescot G., et al. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. Lancet. 2017; 390: 737–746.
419. Garg A., Garg L., Agarwal M., et al. Routine invasive versus selective invasive strategy in elderly patients older than 75 years with non-ST-segment elevation acute coronary syndrome: a systematic review and meta-analysis. Mayo Clin Proc. 2018; 93: 436–444.
420. Rodriguez A.E., Rodriguez-Granillo A.M., Ascarrunz S.D., et al. Did prasugrel and ticagrelor offer the same benefit in patients with acute coronary syndromes after percutaneous coronary interventions compared to clopidogrel? Insights from randomized clinical trials, registries and meta-analysis. Curr Pharm Des. 2018; 24: 465–477.
421. Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791–1800.
422. Valgimigli M., Frigoli E., Leonardi S., et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015; 373: 997–1009.
423. Khan S.U., Arshad A., Riaz I.B., et al. Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome. Am J Cardiol. 2018; 121: 301–307.
424. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387–2397.
425. Tegn N., Abdelnoor M., Aaberge L., et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (after eighty study): an open-label randomised controlled trial. Lancet. 2016; 387: 1057–1065.
426. Kofoed K.F., Kelbaek H., Hansen P.R., et al. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome. Circulation. 2018; 138: 2741–2750.
427. Gaffar R., Habib B., Filion K.B., et al. Optimal timing of complete revascularization in acute coronary syndrome: a systematic review and meta-analysis. J Am Heart Assoc. 2017; 6: 1–11.
428. Feinberg J., Nielsen E.E., Greenhalgh J., et al. Drug-eluting stents versus bare-metal stents for acute coronary syndrome. Cochrane Database Syst Rev. 2017; 8: CD012481.
429. Libby P., Pasterkamp G., Crea F., et al. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019; 124: 150–160.
430. Fanaroff A.C., Rymer J.A., Goldstein S.A., et al. Does this patient with chest pain have acute coronary syndrome? The rational clinical examination systematic review. JAMA. 2015; 314: 1955–1965.
431. Nejatian A., Omstedt ?., H?ijer J., et al. Outcomes in patients with chest pain discharged after evaluation using a high-sensitivity troponin T assay. J Am Coll Cardiol. 2017; 69: 2622–2630.
432. Twerenbold R., Boeddinghaus J., Nestelberger T., et al. Clinical use of high-sensitivity cardiac troponin in patients with suspected myocardial infarction. J Am Coll Cardiol. 2017; 70: 996–1012.
433. Hollander J.E., Than M., Mueller C. State-of-the-art evaluation of emergency department patients presenting with potential acute coronary syndromes. Circulation. 2016; 134: 547–564.
434. Peacock W.F., Baumann B.M., Bruton D., et al. Efficacy of high-sensitivity troponin T in identifying very-low-risk patients with possible acute coronary syndrome. JAMA Cardiol. 2018; 3: 104–111.
435. Andruchow J.E., Kavsak P.A., McRae A.D. Contemporary emergency department management of patients with chest pain: a concise review and guide for the high-sensitivity troponin era. Can J Cardiol. 2018; 34: 98–108.
436. Rodriguez F., Mahaffey K.W. Management of patients with NSTE-ACS: a comparison of the recent AHA/ACC and ESC guidelines. J Am Coll Cardiol. 2016; 68: 313–321.
437. Levine G.N., Bates E.R., Bittl J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016; 68: 1082–1115.
438. Vavuranakis M., Kariori M., Siasos G., et al. Statins in acute coronary syndromes. Curr Pharm Des. 2017; 23: 7086–7098.
439. Goel K., Gupta T., Kolte D., et al. Outcomes and temporal trends of inpatient percutaneous coronary intervention at centers with and without on-site cardiac surgery in the United States. JAMA Cardiol. 2017; 2: 25–33.
440. Van Horn L., Carson J.A., Appel L.J., et al. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation. 2016; 134: e505–e529.
441. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APha/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017; e13–e115.
442. Garvey W.T., Mechanick J.I., Brett E.M., et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016; 22 (suppl 3): 1–203.
443. Chapman A.R., Lee K.K., McAllister D.A., et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. JAMA. 2017; 318: 1913–1924.
444. Roos A., Bandstein N., Lundb?ck M., et al. Stable high-sensitivity cardiac troponin T levels and outcomes in patients with chest pain. J Am Coll Cardiol. 2017; 70: 2226–2236.
445. Sabate M., Brugaletta S., Cequier A., et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 2016; 387: 357–366.
446. Wald D.S., Morris J.K., Wald N.J., et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013; 369: 1115–1123.
447. Engstrom T., Kelbaek H., Helqvist S., et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015; 386: 665–671.
448. Thiele H., Akin I., Sandri M., et al. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018; 379: 1699–1710.
449. Smits P.C., Abdel-Wahab M., Neumann F.J., et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017; 376: 1234–1244.
450. Spencer F.A., Sekercioglu N., Prasad M., et al. Culprit vessel versus immediate complete revascularization in patients with ST-segment myocardial infarction-a systematic review. Am Heart J. 2015; 170: 1133–1139.
451. Valgimigli M., Frigoli E., Leonardi S., et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018; 392: 835–848.
452. Jinatongthai P., Kongwatcharapong J., Foo C.Y., et al. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet. 2017; 390: 747–759.
453. Hofmann R., Witt N., Lagerqvist B., et al. Oxygen therapy in ST-elevation myocardial infarction. Eur Heart J. 2018; 39: 2730–2739.
454. Hofmann R., James S.K., Jernberg T., et al. Oxygen therapy in suspected acute myocardial infarction. N Engl J Med. 2017; 377: 1240–1249.
455. Roolvink V., Ib??ez B., Ottervanger J.P., et al. Early intravenous beta-blockers in patients with STsegment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol. 2016; 67: 2705–2715.
456. Bhatt D.L., Stone G.W., Mahaffey K.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013; 368: 1303–1313.
457. Erlinge D., Omerovic E., Frobert O., et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017; 377: 1132–1142.
458. Dewilde W.J., Oirbans T., Verheugt F.W., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an openlabel, randomised, controlled trial. Lancet. 2013; 381: 1107–1115.
459. Gibson C.M., Mehran R., Bode C., et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016; 375: 2423–2434.
460. Mauri L., Kereiakes D.J., Yeh R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drugeluting stents. N Engl J Med. 2014; 371: 2155–2166.
461. Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791–1800.
462. Ridker P.M., Everett B.M., Thuren T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377: 1119–1131.
463. Anderson L., Sharp G.A., Norton R.J., et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2017; 6: CD007130.
464. Thygesen K., Alpert J.S., Jaffe A.S., et al. Fourth universal definition of myocardial infarction. J Am Coll Cardiol. 2018; 72: 2231–2264.
465. Reynolds K., Go A.S., Leong T.K., et al. Trends in incidence of hospitalized acute myocardial infarction in the cardiovascular research network (CVRN). Am J Med. 2017; 130: 317–327.
466. Montone R.A., Niccoli G., Fracassi F., et al. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. Eur Heart J. 2018; 39: 91–98.
467. Natarajan P., Young R., Stitziel N.O., et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017; 135: 2091–2101.
468. Reed G.W., Rossi J.E., Cannon C.P. Acute myocardial infarction. Lancet. 2017; 389: 197–210.
469. Miranda D.F., Lobo A.S., Walsh B., et al. New insights into the use of the 12-lead electrocardiogram for diagnosing acute myocardial infarction in the emergency department. Can J Cardiol. 2018; 34: 132–145.
470. Twerenbold R., Neumann J.T., Sorensen N.A., et al. Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarction. J Am Coll Cardiol. 2018; 72: 620–632.
471. Eggers K.M., Jernberg T., Lindahl B. Cardiac troponin elevation in patients without a specific diagnosis. J Am Coll Cardiol. 2019; 73: 1–9.
472. Ibanez B., James S., Agewall S., et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39: 119–177.
473. Anderson J.L., Morrow D.A. Acute myocardial infarction. N Engl J Med. 2017; 376: 2053–2064.
474. Levine G.N., Bates E.R., Blankenship J.C., et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2016; 133: 1135–1147.
475. Puerto E., Viana-Tejedor A., Mart?nez-Sell?s M., et al. Temporal trends in mechanical complications of acute myocardial infarction in the elderly. J Am Coll Cardiol. 2018; 72: 959–966.
476. Bahit M.C., Kochar A., Granger C.B. Post-myocardial infarction heart failure. JACC Heart Fail. 2018; 6: 179–186.
477. Durko A.P., Budde R.P.J., Geleijnse M.L., et al. Recognition, assessment and management of the mechanical complications of acute myocardial infarction. Heart. 2018; 104: 1216–1223.
478. Maniwa N., Fujino M., Nakai M., et al. Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction. Eur Heart J. 2018; 39: 201–208.
479. Vavuranakis M., Kariori M., Siasos G., et al. Statins in acute coronary syndromes. Curr Pharm Des. 2017; 23: 7086–7098.
480. Lloyd-Jones D.M., Morris P.B., Ballantyne C.M., et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017; 70: 1785–1822.
481. Yeh R.W., Secemsky E.A., Kereiakes D.J., et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016; 315: 1735–1749.
482. Dahl Aarvik M., Sandven I., Dondo T.B., et al. Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019; 5: 12–20.
483. Bucholz E.M., Butala N.M., Ma S., et al. Life expectancy after myocardial infarction, according to hospital performance. N Engl J Med. 2016; 375: 1332–1342.
484. Andersson H.B., Pedersen F., Engstrom T., et al. Long-term survival and causes of death in patients with ST-elevation acute coronary syndrome without obstructive coronary artery disease. Eur Heart J. 2018; 39: 102–110.
485. Acharya T., Aspelund T., Jonasson T.F., et al. Association of unrecognized myocardial infarction with long-term outcomes in community-dwelling older adults: the ICELAND MI study. JAMA Cardiol. 2018; 3: 1101–1106.
486. Saberi S., Wheeler M., Bragg-Gresham J., et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial. JAMA. 2017; 317: 1349–1357.
487. Axelsson A., Iversen K., Vejlstrup N., et al. Functional effects of losartan in hypertrophic cardiomyopathy — a randomised clinical trial. Heart. 2016; 102: 285–291.
488. Olivotto I., Camici P.G., Merlini P.A., et al. Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail. 2018; 11: 1–10.
489. Lu C., Qin F., Yan Y., et al. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials. J Cardiovasc Med (Hagerstown). 2016; 17: 631–637.
490. Alba A.C., Foroutan F., Duero Posada J., et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart. 2018; 104: 230–236.
491. Bosch X., Rovira M., Sitges M., et al. Enalapril and caRvedilol for preventing ChemOtherapy-induced left ventricular systolic dysfunction in patients with malignant hEmopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol. 2013; 61: 2355–2362.
492. Avila M.S., Ayub-Ferreira S.M., de Barros Wanderley M.R. Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018; 71: 2281–2290.
493. Hilfiker-Kleiner D., Haghikia A., Berliner D., et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017; 38: 2671–2679.
494. Maurer M.S., Schwartz J.H., Gundapaneni B., et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018; 379: 1007–1016.
495. Solomon S.D., Adams D., Kristen A., et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO study. Circulation. 2018. [Epub ahead of print.]
496. Marian A.J., Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017; 121: 749–770.
497. Cecchi F., Iascone M., Maurizi N., et al. Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy. JAMA Cardiol. 2017; 2: 1147–1151.
498. Veselka J., Anavekar N.S., Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017; 389: 1253–1267.
499. Geske J.B., Ommen S.R., Gersh B.J. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018; 6: 364–375.
500. O’Mahony C., Jichi F., Ommen S.R., et al. An international external validation study of the 2014 European society of cardiology guideline on sudden cardiac death prevention in hypertrophic cardiomyopathy (evidence from HCM). Circulation. 2018; 137: 1015–1023.
501. Maron B.J. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018; 379: 655–668.
502. Maron M.S., Rowin E.J., Olivotto I., et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016; 67: 1399–1409.
503. Porez-Molina J.A., Molina I. Chagas disease. Lancet. 2018; 391: 82–94.
504. Mahmood S.S., Fradley M.G., Cohen J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018; 71: 1755–1764.
505. Frustaci A., Chimenti C. Immunosuppressive therapy in myocarditis. Circ J. 2015; 79: 4–7.
506. Xu J., Brooks E.G. Giant cell myocarditis: a brief review. Arch Pathol Lab Med. 2016; 140: 1429–1434.
507. McNally E.M., Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res. 2017; 121: 731–748.
508. Weintraub R.G., Semsarian C., Macdonald P. Dilated cardiomyopathy. Lancet. 2017; 390: 400–414.
509. Bozkurt B., Colvin M., Cook J., et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016; 134: e579–e646.
510. Hershberger R.E., Givertz M.M., Ho C.Y., et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018; 20: 899–909.
511. Henriksen P.A. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018; 104: 971–977.
512. Koenig T., Hilfiker-Kleiner D., Bauersachs J. Peripartum cardiomyopathy. Herz. 2018; 43: 431–437.
513. Cruz M.O., Briller J., Hibbard J.U. New insights in peripartum cardiomyopathy. Obstet Gynecol Clin North Am. 2018; 45: 281–298.
514. Oomen A., Semsarian C., Puranik R., et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy: progress and pitfalls. Heart Lung Circ. 2018; 27: 1310–1317.
515. Wang W., James C.A., Calkins H. Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient. Europace. 2019; 21: 9–21.
516. Pereira N.L., Grogan M., Dec G.W. Spectrum of restrictive and infiltrative cardiomyopathies: part 1 of a 2-part series. J Am Coll Cardiol. 2018; 71: 1130–1148.
517. Pereira N.L., Grogan M., Dec G.W. Spectrum of restrictive and infiltrative cardiomyopathies: part 2 of a 2-part series. J Am Coll Cardiol. 2018; 71: 1149–1166.
518. Birnie D.H., Kandolin R., Nery P.B., et al. Cardiac manifestations of sarcoidosis: diagnosis and management. Eur Heart J. 2017; 38: 2663–2670.
519. Siddiqi O.K., Ruberg F.L. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018; 28: 10–21.
520. Quarta C.C., Gonzalez-Lopez E., Gilbertson J.A., et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017; 38: 1905–1908.
521. Finsterer J., Stollberger C., Towbin J.A. Left ventricular noncompaction cardiomyopathy: cardiac, neuromuscular, and genetic factors. Nat Rev Cardiol. 2017; 14: 224–237.
522. Lyon A.R., Bossone E., Schneider B., et al. Current state of knowledge on takotsubo syndrome: a position statement from the taskforce on takotsubo syndrome of the heart failure association of the European Society of Cardiology. Eur J Heart Fail. 2016; 18: 8–27.
523. Scally C., Rudd A., Mezincescu A., et al. Persistent long-term structural, functional, and metabolic changes after stress-induced (Takotsubo) cardiomyopathy. Circulation. 2018; 137: 1039–1048.
524. Brambatti M., Matassini M.V., Adler E.D., et al. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017; 70: 2363–2375.
525. Grimaldi A., Mocumbi A.O., Freers J., et al. Tropical endomyocardial fibrosis: natural history, challenges, and perspectives. Circulation. 2016; 133: 2503–2515.
526. Edwards N.C., Yuan M., Nolan O., et al. Effect of valvular surgery in carcinoid heart disease: an observational cohort study. J Clin Endocrinol Metab. 2016; 101: 183–190.
527. Nomoto N., Tani T., Konda T., et al. Primary and metastatic cardiac tumors: echocardiographic diagnosis, treatment and prognosis in a 15-years single center study. J Cardiothorac Surg. 2017; 12: 1–9.
528. Park DS, Fishman GI. Development and function of the cardiac conduction system in health and disease. J Cardiovasc Dev Dis. 2017; 4: 1–16.
529. Carmeliet E. Pacemaking in cardiac tissue. From IK2 to a coupled-clock system. Physiol Rep. 2019; 7: 1–11.
530. Savio-Galimberti E, Argenziano M, Antzelevitch C. Cardiac arrhythmias related to sodium channel dysfunction. Handb Exp Pharmacol. 2018; 246: 331–354.
531. Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol. 2016; 13: 36–47.
532. Mosley JD, Shoemaker MB, Wells QS, et al. Investigating the genetic architecture of the PR interval using clinical phenotypes. Circ Cardiovasc Genet. 2017; 10: 1–23.
533. Di Diego JM, Antzelevitch C. J wave syndromes as a cause of malignant cardiac arrhythmias. Pacing Clin Electrophysiol. 2018; 41: 684–699.
534. Steinhubl S.R., Waalen J., Edwards A.M., et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA. 2018; 320: 146–155.
535. Solbiati M., Costantino G., Casazza G., et al. Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope. Cochrane Database Syst Rev. 2016; 4: CD011637.
536. Sheldon R., Raj S.R., Rose M.S., et al. Fludrocortisone for the prevention of vasovagal syncope: a randomized, placebo-controlled trial. J Am Coll Cardiol. 2016; 68: 1–9.
537. Izcovich A., Gonzalez Malla C., Manzotti M., et al. Midodrine for orthostatic hypotension and recurrent reflex обморок: a systematic review. Neurology. 2014; 83: 1170–1177.
538. Flevari P., Leftheriotis D., Repasos E., et al. Fluoxetine vs. placebo for the лечение of recurrent vasovagal syncope with anxiety sensitivity. Europace. 2017; 19: 127–131.
539. Brignole M., Menozzi C., Moya A., et al. Pacemaker therapy in patients with neurally mediated syncope and documented asystole. Third international study on syncope of uncertain etiology (ISSUE-3): a randomized trial. Circulation. 2012; 125: 2566–2571.
540. Baron-Esquivias G., Morillo C.A., Moya-Mitjans A., et al. Dual-chamber pacing with closed loop stimulation in recurrent reflex vasovagal syncope: the SPAIN Study. J Am Coll Cardiol. 2017; 70: 1720–1728.
541. Hamon D., Blaye-Felice M.S., Bradfield J.S., et al. A new combined parameter to predict premature ventricular complexes induced cardiomyopathy: impact and recognition of epicardial origin. J Cardiovasc Electrophysiol. 2016; 27: 709–717.
542. Prandoni P., Lensing A.W., Prins M.H., et al. Prevalence of pulmonary embolism among patients hospitalized for syncope. N Engl J Med. 2016; 375: 1524–1531.
543. Thiruganasambandamoorthy V., Stiell I.G., Sivilotti M.L.A., et al. Predicting short-term risk of arrhythmia among patients with syncope: the Canadian Syncope Arrhythmia Risk Score. Acad Emerg Med. 2017; 24: 1315–1326.
544. Freeman R., Abuzinadah A.R., Gibbons C., et al. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 2018; 72: 1294–1309.
545. Shen W.K., Sheldon R.S., Benditt D.G., et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017; 136: e25–e59.
546. Padmanabhan D., Kancharla K., El-Harasis M.A., et al. Diagnostic and therapeutic value of implantable loop recorder: a tertiary care center experience. Pacing Clin Electrophysiol. 2019; 42: 38–45.
547. Pournazari P., Oqab Z., Sheldon R. Diagnostic value of neurological studies in diagnosing syncope: a systematic review. Can J Cardiol. 2017; 33: 1604–1610.
548. Brignole M., Moya A., de Lange F.J., et al. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J. 2018; 39: 1883–1948.
549. Costantino G., Sun B.C., Barbic F., et al. Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department. Eur Heart J. 2016; 37: 1493–1498.
550. Varosy P.D., Chen L.Y., Miller A.L., et al. Pacing as a treatment for reflex-mediated (vasovagal, situational, or carotid sinus hypersensitivity) syncope: a systematic review for the 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017; 136: e123–e135.
551. Ringh M, Rosenqvist M, Hollenberg J, et al. Mobile-phone dispatch of laypersons for CPR in out of-hospital cardiac arrest. N Engl J Med. 2015; 372: 2316–2325.
552. Nichol G, Leroux B, Wang H, et al. Trial of continuous or interrupted chest compressions during CPR. N Engl J Med. 2015; 373: 2203–2214.
553. Zhan L, Yang LJ, Huang Y, et al. Continuous chest compression versus interrupted chest compression for cardiopulmonary resuscitation of non-asphyxial out-of-hospital cardiac arrest. Cochrane Database Syst Rev. 2017; 3: CD010134.
554. Kirkegaard H, Soreide E, de Haas I, et al. Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital cardiac arrest: a randomized clinical trial. JAMA. 2017; 318: 341–350.
555. Holmberg MJ, Vognsen M, Andersen MS, et al. Bystander automated external defibrillator use and clinical outcomes after out-of-hospital cardiac arrest: a systematic review and meta-analysis. Resuscitation. 2017; 120: 77–87.
556. Perkins GD, Ji C, Deakin CD, et al. A randomized trial of epinephrine in out-of-hospital cardiac arrest. N Engl J Med. 2018; 379: 711–721.
557. Zhang Q, Liu B, Zhao L, et al. Efficacy of vasopressin-epinephrine compared to epinephrine alone for out of hospital cardiac arrest patients: a systematic review and meta-analysis. Am J Emerg Med. 2017; 35: 1555–1560.
558. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; 374: 1711–1722.
559. Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA. 2013; 310: 270–279.
560. Lilja G, Nielsen N, Friberg H, et al. Cognitive function in survivors of out-of-hospital cardiac arrest after target temperature management at 33°C versus 36°C. Circulation. 2015; 131: 1340–1349.
561. Kolodziejczak M, Andreotti F, Kowalewski M, et al. Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: a systematic review and meta-analysis. Ann Intern Med. 2017; 167: 103–111.
562. Wong CX, Brown A, Lau DH, et al. Epidemiology of sudden cardiac death: global and regional perspectives. Heart Lung Circ. 2019; 28: 6–14.
563. Myerburg RJ, Goldberger JJ. Sudden cardiac arrest risk assessment: population science and the individual risk mandate. JAMA Cardiol. 2017; 2: 689–694.
564. Landry CH, Allan KS, Connelly KA, et al. Sudden cardiac arrest during participation in competitive sports. N Engl J Med. 2017; 377: 1943–1953.
565. Emery MS, Kovacs RJ. Sudden cardiac death in athletes. JACC Heart Fail. 2018; 6: 30–40.
566. Mellor G, Laksman ZWM, Tadros R, et al. Genetic testing in the evaluation of unexplained cardiac arrest: from the CASPER (cardiac arrest survivors with preserved ejection fraction registry). Circ Cardiovasc Genet. 2017; 10: 1–8.
567. Tseng Z, Olgin J, Vittinghoff E, et al. Prospective countywide surveillance and autopsy characterization of sudden cardiac death: the San Francisco postmortem systematic investigation of sudden cardiac death (POSTSCD) study. Circulation. 2018; 137: 2689–2700.
568. Myat A, Song KJ, Rea T. Out-of-hospital cardiac arrest: current concepts. Lancet. 2018; 391: 970–979.
569. Ong MEH, Perkins GD, Cariou A. Out-of-hospital cardiac arrest: prehospital management. Lancet. 2018; 391: 980–988.
570. Bobrow BJ, Spaite DW, Vadeboncoeur TF, et al. Implementation of a regional telephone cardiopulmonary resuscitation program and outcomes after out-of-hospital cardiac arrest. JAMA Cardiol. 2016; 1: 294–302.
571. Chan PS, Berg RA, Tang Y, et al. Association between therapeutic hypothermia and survival after in-hospital cardiac arrest. JAMA. 2016; 316: 1375–1382.
572. Baekgaard JS, Viereck S, Moller TP, et al. The effects of public access defibrillation on survival after out-of-hospital cardiac arrest: a systematic review of observational studies. Circulation. 2017; 136: 954–965.
573. Nichol G, Sayre MR, Guerra F, et al. Defibrillation for ventricular fibrillation: a shocking update. J Am Coll Cardiol. 2017; 70: 1496–1509.
574. Geocadin RG, Wijdicks E, Armstrong MJ, et al. Practice guideline summary: reducing brain injury following cardiopulmonary resuscitation: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2017; 88: 2141–2149.
575. Hassager C, Nagao K, Hildick-Smith D. Out-of-hospital cardiac arrest: in-hospital intervention strategies. Lancet. 2018; 391: 989–998.
576. Kragholm K, Wissenberg M, Mortensen RN, et al. Bystander efforts and 1-year outcomes in out-ofhospital cardiac arrest. N Engl J Med. 2017; 376: 1737–1747.
577. Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013; 368: 1585–1593.
578. Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet. 2015; 386: 1747–1753.
579. Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016; 374: 1911–1921.
580. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014; 35: 3346–3355.
581. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016; 388: 1995–2003.
582. Chen C, Zhou X, Zhu M, et al. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. J Interv Card Electrophysiol. 2018; 52: 9–18.
583. Duytschaever M, Demolder A, Phlips T, et al. Pulmonary vein isolation with vs. without continued antiarrhythmic drug treatment in subjects with recurrent atrial fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018; 39: 1429–1437.
584. Zhu M, Zhou X, Cai H, et al. Catheter ablation versus medical rate control for persistent atrial fibrillation in patients with heart failure: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95: 1–7.
585. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417–427.
586. Friedman DJ, Black-Maier EW, Barnett AS, et al. Left atrial appendage electrical isolation for treatment of recurrent atrial fibrillation: a meta-analysis. JACC Clin Electrophysiol. 2018; 4: 112–120.
587. Nielsen JC, Johannessen A, Raatikainen P, et al. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. Heart. 2017; 103: 368–376.
588. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as firstline treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014; 311: 692–700.
589. Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015; 372: 1399–1409.
590. Lopez-Lopez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2018; 359: 1–13.
591. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377: 1513–1524.
592. Bennaghmouch N, de Veer A, Bode K, et al. Efficacy and safety of the use of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation and concomitant aspirin therapy: a meta-analysis of randomized trials. Circulation. 2018; 137: 1117–1129.
593. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015; 373: 823–833.
594. Byrnes TJ, Costantini O. Tachyarrhythmias and bradyarrhythmias: differential diagnosis and initial management in the primary care office. Med Clin North Am. 2017; 101: 495–506.
595. Dharod A, Soliman EZ, Dawood F, et al. Association of asymptomatic bradycardia with incident cardiovascular disease and mortality: the multi-ethnic study of atherosclerosis (MESA). JAMA Intern Med. 2016; 176: 219–227.
596. Huang BT, Huang FY, Peng Y, et al. Relation of premature atrial complexes with stroke and death: systematic review and meta-analysis. Clin Cardiol. 2017; 40: 962–969.
597. Katritsis DG, Josephson ME. Classification, electrophysiological features and therapy of atrioventricular nodal reentrant tachycardia. Arrhythm Electrophysiol Rev. 2016; 5: 130–135.
598. Di Biase L, Gianni C, Bagliani G, et al. Arrhythmias involving the atrioventricular junction. Card Electrophysiol Clin. 2017; 9: 435–452.
599. Cosio FG. Atrial flutter, typical and atypical: a review. Arrhythm Electrophysiol Rev. 2017; 6: 55–62.
600. Brunner S, Herbel R, Drobesch C, et al. Alcohol consumption, sinus tachycardia, and cardiac arrhythmias at the Munich Octoberfest: results from the Munich beer related electrocardiogram workup study (MunichBREW). Eur Heart J. 2017; 38: 2100–2106.
601. Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci?n Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J. 2018; 39: 1442–1445.
602. Koruth JS, Lala A, Pinney S, et al. The clinical use of ivabradine. J Am Coll Cardiol. 2017; 70: 1777–1784.
603. Andrade JG, Macle L, Nattel S, et al. Contemporary atrial fibrillation management: a comparison of the current AHA/ACC/HRS, CCS, and ESC guidelines. Can J Cardiol. 2017; 33: 965–976.
604. Van Gelder IC, Rienstra M, Crijns HJ, et al. Rate control in atrial fibrillation. Lancet. 2016; 388: 818–828.
605. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet. 2016; 388: 829–840.
606. Pallisgaard JL, Gislason GH, Hansen J, et al. Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study. Eur Heart J. 2018; 39: 442–449.
607. Conti S, Verma A. Should ablation be first-line therapy for patients with paroxysmal AF? Curr Treat Options Cardiovasc Med. 2017; 19: 1–11.
608. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39: 1330–1393.
609. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018; 154: 1121–1201.
610. Fanaroff AC, Ohman EM. Non-vitamin K antagonist oral anticoagulants in the treatment of atrial fibrillation. Annu Rev Med. 2018. [Epub ahead of print.]
611. Brennan Y, Favaloro EJ, Pasalic L, et al. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. Intern Med J. 2019; 49: 59–65.
612. Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018; 15: 273–281.
613. Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology clinical expert consensus document task force. J Am Coll Cardiol. 2017; 69: 871–898.
614. Ortiz M, Martin A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017; 38: 1329–1335.
615. Kolodziejczak M, Andreotti F, Kowalewski M, et al. Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: a systematic review and metaanalysis. Ann Intern Med. 2017; 167: 103–111.
616. Alba AC, Foroutan F, Duero Posada J, et al. Implantable cardiac defibrillator and mortality in nonischaemic cardiomyopathy: an updated meta-analysis. Heart. 2018; 104: 230–236.
617. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016; 375: 1221–1230.
618. Claro JC, Candia R, Rada G, et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev. 2015; 12: CD008093.
619. Lahrouchi N, Raju H, Lodder EM, et al. Utility of post-mortem genetic testing in cases of sudden arrhythmic death syndrome. J Am Coll Cardiol. 2017; 69: 2134–2145.
620. Kosmidou I, Embacher M, McAndrew T, et al. Early ventricular tachycardia or fibrillation in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention and impact on mortality and stent thrombosis (from the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial). Am J Cardiol. 2017; 120: 1755–1760.
621. Michowitz Y, Tovia-Brodie O, Heusler I, et al. Differentiating the QRS morphology of posterior fascicular ventricular tachycardia from right bundle branch block and left anterior hemiblock aberrancy. Circ Arrhythm Electrophysiol. 2017; 10: 1–11.
622. Te ALD, Wu TC, Lin YJ, et al. Increased risk of ventricular tachycardia and cardiovascular death in patients with myocarditis during the long-term follow-up: a national representative cohort from the national health insurance research database. Medicine (Baltimore). 2017; 96: 1–17.
623. Maron BJ, Maron MS. LGE means better selection of HCM patients for primary prevention implantable defibrillators. JACC Cardiovasc Imaging. 2016; 9: 1403–1406.
624. Mazzanti A, Ng K, Faragli A, et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol. 2016; 68: 2540–2550.
625. Crotti L, Kotta MC. The role of genetics in primary ventricular fibrillation, inherited channelopathies and cardiomyopathies. Int J Cardiol. 2017; 237: 45–48.
626. Vergara P, Tung R, Vaseghi M, et al. Successful ventricular tachycardia ablation in patients with electrical storm reduces recurrences and improves survival. Heart Rhythm. 2018; 15: 48–55.
627. Agarwal V, Vittinghoff E, Whitman IR, et al. Relation between ventricular premature complexes and incident heart failure. Am J Cardiol. 2017; 119: 1238–1242.
628. Bennett M, Parkash R, Nery P, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 implantable cardioverter-defibrillator guidelines. Can J Cardiol. 2017; 33: 174–188.
629. Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018; 72: 1653–1676.
630. Pathak RK, Ariyarathna N, Garcia FC, et al. Catheter ablation of idiopathic ventricular arrhythmias. Heart Lung Circ. 2019; 28: 102–109.
631. Wolf M, Sacher F, Cochet H, et al. Long-term outcome of substrate modification in ablation of post-myocardial infarction ventricular tachycardia. Circ Arrhythm Electrophysiol. 2018; 11: 1–14.
632. Telles-Garcia N, Dahal K, Kocherla C, et al. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and metaanalysis. Int J Cardiol. 2018; 268: 143–148.
633. Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018; 39: 2959–2971.
634. Nazarian S, Hansford R, Rahsepar AA, et al. Safety of magnetic resonance imaging in patients with cardiac devices. N Engl J Med. 2017; 377: 2555–2564.
635. Kolodziejczak M, Andreotti F, Kowalewski M, et al. Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: a systematic review and meta-analysis. Ann Intern Med. 2017; 167: 103–111.
636. Zeitler EP, Friedman DJ, Daubert JP, et al. Multiple comorbidities and response to cardiac resynchronization therapy: MADIT-CRT long-term follow-up. J Am Coll Cardiol. 2017; 69: 2369–2379.
637. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016; 375: 1221–1230.
638. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016; 374: 2235–2245.
639. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016; 133: 1637–1644.
640. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417–427.
641. Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol. 2017; 70: 1949–1961.
642. Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage isolation in patients with longstanding persistent AF undergoing catheter ablation: BELIEF trial. J Am Coll Cardiol. 2016; 68: 1929–1940.
643. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016; 375: 111–121.
644. Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015; 372: 1399–1409.
645. Shulman RM, Hunt B. Cardiac implanted electronic devices and MRI safety in 2018—the state of play. Eur Radiol. 2018; 28: 4062–4065.
646. Russo RJ, Costa HS, Silva PD, et al. Assessing the risks associated with MRI in patients with a pacemaker or defibrillator. N Engl J Med. 2017; 376: 755–764.
647. Tjong FV, Reddy VY. Permanent leadless cardiac pacemaker therapy: a comprehensive review. Circulation. 2017; 135: 1458–1470.
648. Patel B, Garg J, Chaudhary R, et al. His bundle pacing: hemodynamics and clinical outcomes. Cardiol Rev. 2018; 26: 201–206.
649. Honarbakhsh S, Hunter L, Chow A, et al. Bradyarrhythmias and pacemakers. BMJ. 2018; 360: 1–9.
650. Al-Khatib SM, Friedman P, Ellenbogen KA. Defibrillators: selecting the right device for the right patient. Circulation. 2016; 134: 1390–1404.
651. Lampert R, Olshansky B, Heidbuchel H, et al. Safety of sports for athletes with implantable cardioverterdefibrillators: long-term results of a prospective multinational registry. Circulation. 2017; 135: 2310–2312.
652. Boriani G, Nesti M, Ziacchi M, et al. Cardiac resynchronization therapy: an overview on guidelines. Heart Fail Clin. 2017; 13: 117–137.
653. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016; 18: 1609–1678.
654. Lin YJ, Lin CY, Chen SA. Ablation of persistent atrial fibrillation and beyond. Curr Opin Cardiol. 2019; 34: 16–22.
655. Kumar S, Romero J, Mehta NK, et al. Long-term outcomes after catheter ablation of ventricular tachycardia in patients with and without structural heart disease. Heart Rhythm. 2016; 13: 1957–1963.
656. Cuculich PS, Schill MR, Kashani R, et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia. N Engl J Med. 2017; 377: 2325–2336.
657. Than M., Aldous S., Lord S.J., et al. A 2-hour diagnostic protocol for possible cardiac chest pain in the emergency department: a randomized clinical trial. JAMA Intern Med. 2014; 174: 51–58.
658. Foy A.J., Dhruva S.S., Peterson B., et al. Coronary computed tomography angiography vs functional stress testing for patients with suspected coronary artery disease: a systematic review and metaanalysis. JAMA Intern Med. 2017; 177: 1623–1631.
659. Mark D.B., Anstrom K.J., Sheng S., et al. Quality-of-life outcomes with anatomic versus functional diagnostic testing strategies in symptomatic patients with suspected coronary artery disease: results from the PROMISE randomized trial. Circulation. 2016; 133: 1995–2007.
660. Fanaroff A.C., Rymer J.A., Goldstein SA, et al. Does this patient with chest pain have acute coronary syndrome? The rational clinical examination systematic review. JAMA. 2015; 314: 1955–1965.
661. Twerenbold R., Boeddinghaus J., Nestelberger T., et al. Clinical use of high-sensitivity cardiac troponin in patients with suspected myocardial infarction. J Am Coll Cardiol. 2017; 70: 996–1012.
662. Konstam M.A., Kiernan M., Chandler A., et al. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2017; 69: 1409–1419.
663. Draper J., Subbiah S., Bailey R., et al. Murmur clinic: validation of a new model for detecting heart valve disease. Heart. 2019; 105: 56–59.
664. Kagaya Y., Tabata M., Arata Y., et al. Variation in effectiveness of a cardiac auscultation training class with a cardiology patient simulator among heart sounds and murmurs. J Cardiol. 2017; 70: 192–198.
665. Yap F.Y., Skalski M.R., Patel D.B., et al. Hypertrophic osteoarthropathy: clinical and imaging features. Radiographics. 2017; 37: 157–195.
666. Haber R., Khoury R., Kechichian E., et al. Splinter hemorrhages of the nails: a systematic review of clinical features and associated conditions. Int J Dermatol. 2016; 55: 1304–1310.
667. Peacock W.F., Baumann B.M., Bruton D., et al. Efficacy of high-sensitivity troponin T in identifying very-low-risk patients with possible acute coronary syndrome. JAMA Cardiol. 2018; 3: 104–111.
668. Januzzi J.L. Jr, Chen-Tournoux A.A., Christenson R.H., et al. N-terminal pro–B-type natriuretic peptide in the emergency department: the ICON-RELOADED study. J Am Coll Cardiol. 2018; 71: 1191–1200.
669. Silverman M.G., Ference B.A., Im K., et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016; 316: 1289–1297.
670. Ettehad D., Emdin C.A., Kiran A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957–967.
671. Bundy J.D., Li C., Stuchlik P., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017; 2: 775–781.
672. Kalkman D.N., Brouwer T.F., Vehmeijer J.T., et al. J curve in patients randomly assigned to different systolic blood pressure targets: an experimental approach to an observational paradigm. Circulation. 2017; 136: 2220–2229.
673. Estruch R., Ros E., Salas-Salvado J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018; 378: e1–e14.
674. Manson J.E., Cook N.R., Lee I.M., et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019; 380: 33–44.
675. Manson J.E., Cook N.R., Lee I.M., et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019; 380: 23–32.
676. Bowman L., Mafham M., Wallendszus K., et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018; 379: 1540–1550.
677. Aung T., Halsey J., Kromhout D., et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol. 2018; 3: 225–234.
678. Ridker P.M., Everett B.M., Thuren T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377: 1119–1131.
679. Newby D.E., Adamson P.D., Berry C., et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018; 379: 924–933.
680. Guirguis-Blake J.M., Evans C.V., Senger C.A., et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016; 164: 804–813.
681. Karmali K.N., Lloyd-Jones D.M., Berendsen M.A., et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. 2016; 1: 341–349.
682. Reboussin D.M., Allen N.B., Griswold M.E., et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71: 2176–2198.
683. Lindholt J.S., Sogaard R. Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial. Lancet. 2017; 390: 2256–2265.
684. McNeil J.J., Woods R.L., Nelson M.R., et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018; 379: 1499–1508.
685. McNeil J.J., Nelson M.R., Woods R.L., et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018; 379: 1519–1528.
686. McNeil J.J., Wolfe R., Woods R.L., et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018; 379: 1509–1518.
687. Bowman L., Mafham M., Wallendszus K., et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018; 379: 1529–1539.
688. Gaziano J.M., Brotons C., Coppolecchia R., et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebocontrolled trial. Lancet. 2018; 392: 1036–1046.
689. Benjamin E.J., Virani S.S., Callaway C.W., et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018; 137: e67–e492.
690. Roth G.A., Johnson C.O., Abate K.H., et al. The burden of cardiovascular diseases among US states, 1990-2016. JAMA Cardiol. 2018; 3: 375–389.
691. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted lifeyears (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017; 390: 1260–1344.
692. Lassale C., Tzoulaki I., Moons KGM, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J. 2018; 39: 397–406.
693. Hadjiphilippou S., Ray K.K. Lipids and lipoproteins in risk prediction. Cardiol Clin. 2018; 36: 213–220.
694. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71: 2199–2269.
695. de Boer I.H., Bakris G., Cannon CP. Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC/AHA recommendations. JAMA. 2018; 319: 1319–1320.
696. Hales C.M., Fryar C.D., Carroll M.D., et al. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007–2008 to 2015–2016. JAMA. 2018; 319: 1723–1725.
697. Khan S.S., Ning H., Wilkins J.T., et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018; 3: 280–287.
698. Schwingshackl L., Hoffmann G. Diet quality as assessed by the Healthy Eating Index, the Alternate Healthy Eating Index, the Dietary Approaches to Stop Hypertension score, and health outcomes: a systematic review and meta-analysis of cohort studies. J Acad Nutr Diet. 2015; 115: 780–800.
699. Yeboah J., Young R., McClelland R.L., et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016; 67: 139–147.
700. American College of Cardiology. ASCVD risk estimator plus. http://tools.acc.org/ascvd-risk-estimatorplus/#!/calculate/estimate/. Accessed: April 1, 2019.
701. Vu T.H., Lloyd-Jones D.M., Liu K., et al. Optimal levels of all major cardiovascular risk factors in younger age and functional disability in older age: the Chicago Heart Association detection project in industry 32-year follow-up health survey. Circ Cardiovasc Qual Outcomes. 2016; 9: 355–363.
702. Allen N.B., Zhao L., Liu L., et al. Favorable cardiovascular health, compression of morbidity, and healthcare costs: forty-year follow-up of the CHA study (Chicago Heart Association detection project in industry). Circulation. 2017; 135: 1693–1701.
703. Coorey G.M., Neubeck L., Mulley J., et al. Effectiveness, acceptability and usefulness of mobile applications for cardiovascular disease self-management: systematic review with meta-synthesis of quantitative and qualitative data. Eur J Prev Cardiol. 2018; 25: 505–521.
704. Dewey F.E., Gusarova V., Dunbar R.L., et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017; 377: 211–221.
705. Nguyen P.K., Rhee J.W., Wu J.C. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 2016; 1: 831–841.
706. Fisher S.A., Doree C., Taggart D.P., et al. Cell therapy for heart disease: trial sequential analyses of two Cochrane reviews. Clin Pharmacol Ther. 2016; 100: 88–101.
707. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 1: CD004816.
708. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387–2397.
709. Zhu Y., Shen X., Jiang Q., et al. Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events: a meta-analysis of randomized controlled trials. Herz. 2017. [Epub ahead of print.]
710. Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376: 1713–1722.
711. Karatasakis A., Danek B.A., Karacsonyi J., et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017; 6: 1–55.
712. Guirguis-Blake J.M., Evans C.V., Senger C.A., et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016; 164: 804–813.
713. Van der Harst P., van Setten J., Verweij N., et al. 52 genetic loci influencing myocardial mass. J Am Coll Cardiol. 2016; 68: 1435–1448.
714. Kamel H., Bartz T.M., Elkind M.S.V., et al. Atrial cardiopathy and the risk of ischemic stroke in the CHS (Cardiovascular Health Study). Stroke. 2018; 49: 980–986.
715. Roe ?.T., Aronsen J.M., Sk?rdal K., et al. Increased passive stiffness promotes diastolic dysfunction despite improved Ca2+ handling during left ventricular concentric hypertrophy. Cardiovasc Res. 2017; 113: 1161–1172.
716. Lacey B., Herrington W.G., Preiss D., et al. The role of emerging risk factors in cardiovascular outcomes. Curr Atheroscler Rep. 2017; 19: 1–10.
717. Zhao T.X., Mallat Z. Targeting the immune system in atherosclerosis: JACC state-of-the-art review. J Am Coll Cardiol. 2019; 73: 1691–1706.
718. Fredman G., Tabas I. Boosting inflammation resolution in atherosclerosis: the next frontier for therapy. Am J Pathol. 2017; 187: 1211–1221.
719. Jonas DE, Reddy S, Middleton JC, et al. Screening for cardiovascular disease risk with resting or exercise electrocardiography: evidence report and systematic reviewfor the US Preventive Services Task Force. JAMA. 2018; 319: 2315–2328.
720. Palhares DMF, Marcolino MS, Santos TMM, et al. Normal limits of the electrocardiogram derived from a large database of Brazilian primary care patients. BMC Cardiovasc Disord. 2017; 17: 1–23.
721. Yeo TJ, Sharma S. Using the 12-lead electrocardiogram in the care of athletic patients. Cardiol Clin. 2016; 34: 543–555.
722. Skov MW, Rasmussen PV, Ghouse J, et al. Electrocardiographic preexcitation and risk of cardiovascular morbidity and mortality: results from the Copenhagen ECG study. Circ Arrhythm Electrophysiol. 2017; 136: 418–423.
723. Vandenberk B, Vandael E, Robyns T, et al. Which QT correction formulae to use for QT monitoring? J Am Heart Assoc. 2016; 5: 1–10.
724. Mazzanti A, Underwood K, Nevelev D, et al. The new kids on the block of arrhythmogenic disorders: short QT syndrome and early repolarization. J Cardiovasc Electrophysiol. 2017; 28: 1226–1236.
725. Xiong Y, Wang L, Liu W, et al. The prognostic significance of right bundle branch block: a metaanalysis of prospective cohort studies. Clin Cardiol. 2015; 38: 604–613.
726. Cheng YJ, Li ZY, Yao FJ, et al. Early repolarization is associated with a significantly increased risk of ventricular arrhythmias and sudden cardiac death in patients with structural heart diseases. Heart Rhythm. 2017; 14: 1157–1164.
727. Bosson N, Sanko S, Stickney RE, et al. Causes of prehospital misinterpretations of ST elevation myocardial infarction. Prehosp Emerg Care. 2017; 21: 283–290.
728. Garvey JL, Zegre-Hemsey J, Gregg R, et al. Electrocardiographic diagnosis of ST segment elevation myocardial infarction: an evaluation of three automated interpretation algorithms. J Electrocardiol. 2016; 49: 728–732.
729. Sharma S, Drezner JA, Baggish A, et al. International recommendations for electrocardiographic interpretation in athletes. J Am Coll Cardiol. 2017; 69: 1057–1075.
730. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for cardiovascular disease risk with electrocardiography: US Preventive Services Task Force recommendation statement. JAMA. 2018; 319: 2308–2314.
731. American College of Cardiology. Five things physicians and patients should question. Released April 4, 2012; recommendation #5 updated February 28, 2017. http://www.choosingwisely.org/societies/ american-college-of-cardiology/. Accessed January 12, 2019.
732. Johri AM, Poirier P, Dorian P, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position statement on the cardiovascular screening of competitive athletes. Can J Cardiol. 2019; 35: 1–11.
733. Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017; 14: e55–e96.
734. Lindekleiv H, Lochen ML, Mathiesen EB, et al. Echocardiographic screening of the general population and long-term survival: a randomized clinical study. JAMA Intern Med. 2013; 173: 1592–1598.
735. Dudzinski DM, Bhatia RS, Mi MY, et al. Effect of educational intervention on the rate of rarely appropriate outpatient echocardiograms ordered by attending academic cardiologists: a randomized clinical trial. JAMA Cardiol. 2016; 1: 805–812.
736. Bhatia RS, Ivers NM, Yin XC, et al. Improving the appropriate use of transthoracic echocardiography: the Echo WISELY trial. J Am Coll Cardiol. 2017; 70: 1135–1144.
737. Otto CM. Textbook of Clinical Echocardiography. 6th ed. Philadelphia: Elsevier; 2018.
738. Luis SA, Chan J, Pellikka PA. Echocardiographic assessment of left ventricular systolic function: an overview of contemporary techniques, including speckle-tracking echocardiography. Mayo Clin Proc. 2019; 94: 125–138.
739. Kimura BJ. Point-of-care cardiac ultrasound techniques in the physical examination: better at the bedside. Heart. 2017; 103: 987–994.
740. Sicari R, Cortigiani L. The clinical use of stress echocardiography in ischemic heart disease. Cardiovasc Ultrasound. 2017; 15: 1–16.
741. Mitter SS, Shah SJ, Thomas JD. A test in context: E/A and E/e’ to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol. 2017; 69: 1451–1464.
742. Steeds RP, Garbi M, Cardim N, et al. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging. 2017; 18: 1191–1204.
743. Kovell LC, Ali MT, Hays AG, et al. Defining the role of point-of-care ultrasound in cardiovascular disease. Am J Cardiol. 2018; 122: 1443–1450.
744. Nascimento BR, Nunes MC, Lopes EL, et al. Rheumatic heart disease echocardiographic screening: approaching practical and affordable solutions. Heart. 2016; 102: 658–664.
745. Roberts K, Cannon J, Atkinson D, et al. Echocardiographic screening for rheumatic heart disease in indigenous Australian children: a cost-utility analysis. J Am Heart Assoc. 2017; 6: 1–14.
746. Muhlestein JB, Lappe DL, Lima JA, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014; 312: 2234–2243.
747. Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med. 2012; 366: 1393–1403.
748. Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med. 2012; 367: 299–308.
749. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015; 372: 1291–1300.
750. Foy AJ, Dhruva SS, Peterson B, et al. Coronary computed tomography angiography vs functional stress testing for patients with suspected coronary artery disease: a systematic review and metaanalysis. JAMA Intern Med. 2017; 177: 1623–1631.
751. Mark DB, Federspiel JJ, Cowper PA, et al. Economic outcomes with anatomical versus functional diagnostic testing for coronary artery disease. Ann Intern Med. 2016;165:94–102.
752. Newby DE, Adamson PD, Berry C, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018; 379: 924–933.
753. Greenwood JP, Ripley DP, Berry C, et al. Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the CE-MARC 2 randomized clinical trial. JAMA. 2016; 316: 1051–1060.
754. Dweck MR, Doris MK, Motwani M, et al. Imaging of coronary atherosclerosis—evolution towards new treatment strategies. Nat Rev Cardiol. 2016; 13: 533–548.
755. Rozanski A, Berman DS. Long-term risk assessment after the performance of stress myocardial perfusion imaging. Cardiol Clin. 2016; 34: 87–99.
756. Huang JY, Huang CK, Yen RF, et al. Diagnostic performance of attenuation-corrected myocardial perfusion imaging for coronary artery disease: a systematic review and meta-analysis. J Nucl Med. 2016; 57: 1893–1898.
757. Gimelli A, Liga R, Duce V, et al. Accuracy of myocardial perfusion imaging in detecting multivessel coronary artery disease: a cardiac CZT study. J Nucl Cardiol. 2017; 24: 687–695.
758. Bajas NS, Singh S, Farag A, et al. The prognostic value on non-perfusion variables obtained during vasodilator stress imaging. J Nucl Cardiol. 2016; 23: 390–413.
759. Hamon M, Geindreau D, Guittet L, et al. Additional diagnostic value of new CT imaging techniques for the functional assessment of coronary artery disease: a meta-analysis. Eur Radiol. 2019. [Epub ahead of print.]
760. Cho I, Al’Aref SJ, Berger A, et al. Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study. Eur Heart J. 2018; 39: 934–941.
761. Nielsen LH, Botker HE, Sorensen HT, et al. Prognostic assessment of stable coronary artery disease as determined by coronary computed tomography angiography: a Danish multicentre cohort study. Eur Heart J. 2017; 38: 413–421.
762. Lehmann N, Erbel R, Mahabadi AA, et al. Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR study (Heinz Nixdorf Recall). Circulation. 2018; 137: 665–679.
763. Liu A, Wijesurendra RS, Liu JM, et al. Gadolinium-free cardiac MR stress T1-mapping to distinguish epicardial from microvascular coronary disease. J Am Coll Cardiol. 2018; 71: 957–968.
764. Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2017; 10: 1180–1193.
765. Valgimigli M, Gagnor A, Calabro P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015; 385: 2465–2476.
766. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018; 379: 250–259.
767. Smits PC, Abdel-Wahab M, Neumann FJ, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017; 376: 1234–1244.
768. Chong E, Poh KK, Lu Q, et al. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast- induced nephropathy during cardiac catheterisation and percutaneous coronary intervention (CONTRAST): a multi-centre, randomised, controlled trial. Int J Cardiol. 2015; 201: 237–242.
769. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017; 389: 1312–1322.
770. Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med. 2016; 164: 406–416.
771. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018; 378: 603–614.
772. Wang N, Qian P, Yan TD, et al. Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and trial sequential analysis. Int J Cardiol. 2016; 206: 143–152.
773. Garcia D, Harbaoui B, van de Hoef TP, et al. Relationship between FFR, CFR and coronary microvascular resistance — practical implications for FFR-guided percutaneous coronary intervention. PLoS ONE. 2019; 14: 1–16.
774. Agrawal A, Ziccardi MR, Witzke C, et al. Cholesterol embolization syndrome: an under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018; 31: 407–415.
775. Slicker K, Lane WG, Oyetayo OO, et al. Daily cardiac catheterization procedural volume and complications at an academic medical center. Cardiovasc Diagn Ther. 2016; 6: 446–452.
776. Sedhai YR, Golamari R, Timalsina S, et al. Contrast-induced nephropathy after cardiac catheterization: culprits, consequences and predictors. Am J Med Sci. 2017; 354: 462–466.
777. Opotowsky AR, Hess E, Maron BA, et al. Thermodilution vs estimated Fick cardiac output measurement in clinical practice: an analysis of mortality from the veterans affairs clinical assessment, reporting, and tracking (VA CART) program and Vanderbilt University. JAMA Cardiol. 2017; 2: 1090–1099.
778. Fiorilli PN, Anwaruddin S, Zhou E, et al. Catheterization laboratory: structural heart disease, devices, and transcatheter aortic valve replacement. Anesthesiol Clin. 2017; 35: 627–639.
779. Khan S.U., Duran C.A., Rahman H., et al. A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea. Eur Heart J. 2018; 39: 2291–2297.
780. Cowie M.R., Woehrle H., Wegscheider K., et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015; 373: 1095–1105.
781. McLellan J., Heneghan C.J., Perera R., et al. B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database Syst Rev. 2016;12:CD008966.
782. Stienen S., Salah K., Moons A.H., et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NTproBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation. 2018; 137: 1671–1683.
783. Metra M., Teerlink J.R. Heart failure. Lancet. 2017; 390: 1981–1995.
784. Conrad N., Judge A., Tran J., et al. Temporal trends and patterns in heart failure incidence: a populationbased study of 4 million individuals. Lancet. 2018; 391: 572–580.
785. Benjamin E.J., Blaha M.J., Chiuve S.E., et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017; 135: e146–e603.
786. Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017; 70: 776–803.
787. Komanduri S., Jadhao Y., Guduru S.S., et al. Prevalence and risk factors of heart failure in the USA: NHANES 2013-2014 epidemiological follow-up study. J Community Hosp Intern Med Perspect. 2017; 7: 15–20.
788. Chow S.L., Maisel A.S., Anand I., et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017; 135: e1054–e1091.
789. Houstis N.E., Eisman A.S., Pappagianopoulos P.P., et al. Exercise intolerance in heart failure with preserved ejection fraction: diagnosing and ranking its causes using personalized O2 pathway analysis. Circulation. 2018; 137: 148–161.
790. Reddy Y.N., Melenovsky V., Redfield M.M., et al. High-output heart failure: a 15-year experience. J Am Coll Cardiol. 2016; 68: 473–482.
791. Valentova M., von Haehling S., Bauditz J., et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur Heart J. 2016; 37: 1684–1691.
792. Morales-Rull J.L., Bielsa S., Conde-Martel A., et al. Pleural effusions in acute decompensated heart failure: prevalence and prognostic implications. Eur J Intern Med. 2018; 52: 49–53.
793. Konstam M.A., Kiernan M.S., Bernstein D., et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018; 137: e578–e622.
794. Komiya K., Akaba T., Kozaki Y., et al. A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema. Crit Care. 2017; 21: 1–10.
795. Vogel-Claussen J., Elshafee A.S.M., Kirsch J., et al. ACR Appropriateness Criteria® Dyspnea—suspected cardiac origin. J Am Coll Radiol. 2017; 14: s127–s137.
796. Aimo A., Januzzi J.L. Jr, Vergaro G., et al. Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis. Circulation. 2018; 137: 286–297.
797. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37: 2129–2200.
798. Bax J.J., Di Carli M., Narula J., et al. Multimodality imaging in ischaemic heart failure. Lancet. 2019; 393: 1056–1070.
799. Geske J.B., Anavekar N.S., Nishimura R.A., et al. Differentiation of constriction and restriction: complex cardiovascular hemodynamics. J Am Coll Cardiol. 2016; 68: 2329–2347.
800. Xie X., Atkins E., Lv J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387: 435–443.
801. Bundy J.D., Li C., Stuchlik P., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017; 2: 775–781.
802. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–2128.
803. Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644–657.
804. Holman R.R., Coleman R.L., Chan J.C.N., et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5: 877–886.
805. Green J.B., Bethel M.A., Armstrong P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232–242.
806. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993–1004.
807. Cleland J.G.F., Bunting K.V., Flather M.D., et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018; 39: 26–35.
808. Burnett H., Earley A., Voors A.A., et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail. 2017; 10: 1–12.
809. Aung T., Halsey J., Kromhout D., et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol. 2018; 3: 225–234.
810. McMurray J.J., Krum H., Abraham W.T., et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016; 374: 1521–1532.
811. Zannad F., Anker S.D., Byra W.M., et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018; 379: 1332–1342.
812. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011; 364: 797–805.
813. Packer M., O’Connor C., McMurray J.J.V., et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017; 376: 1956–1964.
814. Keber L., Thune J.J., Nielsen J.C., et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016; 375: 1221–1230.
815. Beggs S.A.S., Jhund P.S., Jackson C.E., et al. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart. 2018; 104: 144–150.
816. Goldenberg I., Kutyifa V., Klein H.U., et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014; 370: 1694–1701.
817. Ruschitzka F., Abraham W.T., Singh J.P., et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013; 369: 1395–1405.
818. Velazquez E.J., Lee K.L., Jones R.H., et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016; 374: 1511–1520.
819. Kobashigawa J., Patel J., Azarbal B., et al. Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial. Circ Heart Fail. 2015; 8: 557–564.
820. Som R., Morris P.J., Knight S.R. Graft vessel disease following heart transplantation: a systemic review of the role of statin therapy. World J Surg. 2014; 38: 2324–2334.
821. Mehra M.R., Goldstein D.J., Uriel N., et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med. 2018; 378: 1386–1395.
822. Pandor A., Thokala P., Gomersall T., et al. Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. Health Technol Assess. 2013; 17: 1–207.
823. Abraham W.T., Stevenson L.W., Bourge R.C., et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016; 387: 453–461.
824. Velazquez E.J., Lee K.L., Jones R.H., et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016; 374: 1511–1520.
825. Marrouche N.F., Brachmann J., Andresen D., et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417–427.
826. White W.B., Saag K.G., Becker M.A., et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378: 1200–1210.
827. Pfeffer M.A., Claggett B., Assmann S.F., et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015; 131: 34–42.
828. Redfield M.M., Anstrom K.J., Levine J.A., et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015; 373: 2314–2324.
829. Acker M.A., Parides M.K., Perrault L.P., et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med. 2014; 370: 23–32.
830. Stone G.W., Lindenfeld J., Abraham W.T., et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018; 379: 2307–2318.
831. Obadia J.F., Messika-Zeitoun D., Leurent G., et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018; 379: 2297–2306.
832. Felker G.M., Anstrom K.J., Adams K.F., et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017; 318: 713–720.
833. Stienen S., Salah K., Moons A.H., et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)- guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-proBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions? Circulation. 2018; 137: 1671–1683.
834. Rogers J.G., Patel C.B., Mentz R.J., et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol. 2017; 70: 331–341.
835. Benjamin E.J., Virani S.S., Callaway C.W., et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018; 137: e67–e492.
836. Yancy C.W., Januzzi J.L. Jr, Allen L.A., et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018; 71: 201–230.
837. Metra M., Teerlink J.R. Heart failure. Lancet. 2017; 390: 1981–1995.
838. Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017; 70: 776–803.
839. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37: 2893–2962.
840. Bahit M.C., Kochar A., Granger C.B. Post-myocardial infarction heart failure. JACC Heart Fail. 2018; 6: 179–186.
841. Hunter B.R., Martindale J., Abdel-Hafez O, et al. Approach to acute heart failure in the emergency department. Prog Cardiovasc Dis. 2017; 60: 178–186.
842. Ellison D.H., Felker G.M. Diuretic treatment in heart failure. N Engl J Med. 2017; 377: 1964–1975.
843. Bennett M., Parkash R., Nery P., et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 implantable cardioverter-defibrillator guidelines. Can J Cardiol. 2017; 33: 174–188.
844. Halloran K.M., Parkes M.D., Chang J., et al. Molecular assessment of rejection and injury in lung transplant biopsies. J Heart Lung Transplant. 2019. [Epub ahead of print.]
845. Chih S., Chong A.Y., Mielniczuk L.M., et al. Allograft vasculopathy: the Achilles’ heel of heart transplantation. J Am Coll Cardiol. 2016; 68: 80–91.
846. Miller L.W., Rogers J.G. Evolution of left ventricular assist device therapy for advanced heart failure: a review. JAMA Cardiol. 2018; 3: 650–658.
847. Miller R.J.H., Teuteberg J.J., Hunt S.A. Innovations in ventricular assist devices for end-stage heart failure. Annu Rev Med. 2019; 70: 33–44.
848. Redfield M.M. Heart failure with preserved ejection fraction. N Engl J Med. 2016; 375: 1868–1877.
849. Feldman T., Mauri L., Kahwash R., et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): a phase 2, randomized, sham-controlled trial. Circulation. 2018; 137: 364–375.
850. Lam C.S.P., Gamble G.D., Ling L.H., et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018; 39: 1770–1780.
851. York M.K., Gupta D.K., Reynolds C.F., et al. B-type natriuretic peptide levels and mortality in patients with and without heart failure. J Am Coll Cardiol. 2018; 71: 2079–2088.
852. Aimo A., Januzzi J.L. Jr, Vergaro G., et al. Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis. Circulation. 2018; 137: 286–297.
853. Kavalieratos D., Gelfman L.P., Tycon L.E., et al. Palliative care in heart failure: rationale, evidence, and future priorities. J Am Coll Cardiol. 2017; 70: 1919–1930.

Труды отечественных авторов при подготовке статей по терапии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.

- Вернуться в оглавление раздела "Терапия"

Редактор: Искандер Милевски. Дата обновления публикации: 29.11.2024